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ABSTRACT 
 
 
 MCL-1, an anti-apoptotic BCL-2 family member that is essential for the survival 
of multiple cell lineages, is also among the most highly amplified genes in cancer.  
Although MCL-1 is known to oppose cell death, precisely how it functions to promote 
survival of normal and malignant cells is poorly understood.  Here, I report that different 
forms of MCL-1 reside in distinct mitochondrial locations and exhibit separable 
functions.  On the outer mitochondrial membrane, a MCL-1 isoform acts like other anti-
apoptotic BCL-2 molecules to antagonize apoptosis, whereas an amino-terminally 
truncated isoform of MCL-1 that is imported into the mitochondrial matrix is necessary 
to facilitate normal mitochondrial fusion, ATP production, membrane potential, 
respiration, cristae ultrastructure, and maintenance of oligomeric ATP synthase.  My 
results provide insight into how MCL-1's surprisingly diverse salutary functions may 
control the survival of both normal and cancer cells. 
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CHAPTER 1.    INTRODUCTION 
 
 
The BCL-2 Family Proteins and Apoptosis 
 
Apoptosis is an essential genetic program required in the regulation of 
development and maintenance of homeostasis of animals.  Dysregulation of apoptosis can 
lead to a variety of human pathologies, including cancer, neurodegenerative, and 
autoimmune diseases (Cory and Adams, 2002).  Two programs that regulate apoptosis 
merge to induce the activation of caspases, which are proteases responsible for the 
demise of a cell.  The extrinsic pathway involves the ligation of death receptors on the 
surface of the cell.  The death receptors (members of the tumor necrosis factor receptor 
superfamily) contain an intracellular death domain that recruits and activates Caspase-8 
(Youle and Strasser, 2008). Caspase-8 is recruited through the adaptor protein Fas-
associated death domain (FADD), resulting in subsequent activation of effector caspases, 
such as Caspase-3 (Youle and Strasser, 2008).  
 
In many cell types, the extrinsic pathway for cell death does not involve BCL-2 
family members or mitochondrial outer membrane permeabilization. The intrinsic cell 
death pathway, however, is regulated by BCL-2 family members and focuses much of its 
effort at the level of the mitochondria (Chipuk et al., 2010). It consists of both pro and 
anti-apoptotic members that share a homology within four conserved regions called BCL-
2 homology domains (BH), which correspond to ?-helical segments (Danial and 
Korsmeyer, 2004; Opferman, 2008) (Fig. 1.1).  Anti-apoptotic BCL-2 family members 
(such as BCL-2, BCL-XL, BCL-W, MCL-1, and A1) share all four BH domains and 
possess a hydrophobic binding pocket that binds the BH3 domain of other family 
members (Fig. 1.1).  The pro-apoptotic BCL-2 family members can be subdivided into 
two groups, the multidomain pro-apoptotic effectors (such as BAX and BAK) which 
have three BH domains and the BH3-only molecules (such as BID, BAD, BIM, PUMA, 
NOXA, etc.) which reside upstream of BAX/BAK activation (Cheng et al., 2001) (Fig. 
1.1).  Death signals activate and/or induce the BH3-only molecules through either 
transcriptional regulation or post-translational modification (Chipuk et al., 2010).  The 
activated BH3 only proteins subsequently promote BAX and BAK oligomerization; a 
process antagonized by anti-apoptotic BCL-2 family members (Cheng et al., 2001) (Fig. 
1.2). Activation and oligomerization of BAX/BAK results in mitochondrial outer 
membrane permeabilization (MOMP) that releases a variety of apoptogenic proteins, 
such as cytochrome c, from the mitochondrial intermembrane space (Goldstein et al., 
2000) (Fig. 1.2).  Cytochrome c then binds to APAF-1, changing its conformation so that 
it can recruit Caspase-9. Once Caspase-9 is bound to APAF-1 it can activate itself. The 
active Caspase-9 then cleaves the effector caspases, such as Caspase-3, resulting in the 
orderly demise of a cell (Opferman and Korsmeyer, 2003) (Fig. 1.2). 
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Figure 1.1. The BCL-2 Family 
Reprinted by permission from Macmillan Publishers Ltd: Opferman, J.T., and 
Korsmeyer, S.J. (2003). Apoptosis in the development and maintenance of the immune 
system. Nat Immunol 4, 410-415.
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Figure 1.2. BCL-2 Family Mediated Apoptosis 
The BCL-2 family integrates death signals from a variety of sources and regulates 
mitochondria-dependent apoptosis. BH3-only family members act as sentinels for many 
death stimuli and can be regulated by transcriptional and post-translational mechanisms, 
allowing rapid response to changing cellular conditions. They can be directly sequestered 
by antiapoptotic BCL-2 family members (e.g. BCL-2, BCL-XL, MCL-1, etc.). Upon 
sufficient activation, BH3-only family members can mediate the activation of the 
multidomain proapoptotics BAX and BAK either by a 'hit and run' interaction or by 
relieving antiapoptotic antagonism of BAX and BAK allowing oligomerization. Upon 
BAX and BAK oligomerization, the mitochondrial outer membrane is permeabilized 
releasing a variety of apoptogenic substrates from the mitochondrial intermembrane 
space, such as cytochrome c, into the cytosol. Released cytochrome c can complex with 
APAF1 and Pro-Caspase-9 to form the apoptosome, which catalyzes Caspase-9 
activation. Activated Caspase-9 can then trigger the activation of a downstream caspase 
cascade leading to cell death.  Reprinted by permission from Macmillan Publishers Ltd: 
Opferman, J.T. (2008). Apoptosis in the development of the immune system. Cell Death 
Differ 15, 234-242. 
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Anti-apoptotic MCL-1 
 
Mcl-1 was initially identified as an early-induced gene during TPA induced 
differentiation in a human myeloid leukemia cell line (ML-1) (Kozopas et al., 1993).  
MCL-1 shares sequence homology to BCL-2 in the carboxy-terminal region where it 
contains three amphipathic alpha-helical segments; however, its amino-terminal region is 
poorly conserved (Kozopas et al., 1993). The amino-terminus of MCL-1 is much longer 
than that of any other anti-apoptotic BCL-2 family member and contains two PEST 
sequences (Kozopas et al., 1993).  In addition, at the carboxy-terminal end, it possesses a 
membrane spanning domain consisting of 20 hydrophobic amino acids, flanked by 
charged residues similar to BCL-2 (Kozopas et al., 1993).  Deletion of either the amino- 
or carboxy-terminus of MCL-1 does not disrupt its ability to bind pro-apoptotic 
molecules (Day et al., 2005). 
  
During murine embryogenesis, MCL-1 expression is rapidly induced after 
fertilization and peaks during the 2-cell through 8-cell stages and then decreases in 
blastocysts (Sano et al., 2000).  MCL-1 is expressed in human epithelial cells of the skin, 
gastrointestinal tract, and pulmonary tissues, in cardiomyocytes, skeletal muscle, 
hematopoietic cells, lymphocytes, uterus, adrenal cortex, sympathetic ganglia, pancreatic 
islets, and hepatocytes (Krajewski et al., 1995).  MCL-1 expression is also regulated by 
growth factor signaling.  Both mature lymphocytes and immature progenitors increase 
MCL-1 expression in response to IL-7 stimulation (Opferman et al., 2003).  
Hematopoietic stem cells also increase Mcl-1 mRNA after exposure to stem cell factor 
(SCF) and IL-6 (Opferman et al., 2005).  Conversely, withdrawal from IL-3 in BAF/3 
cells results in decreased MCL-1 expression (Maurer et al., 2006). 
 
MCL-1 is predominantly localized to the mitochondrial membrane, with some 
distribution also detectable in ER membranes (Germain and Duronio, 2007; Yang et al., 
1995).  Membrane association of MCL-1 depends on the presence of its hydrophobic 
carboxy-terminus which serves as a transmembrane domain (Yang et al., 1995).  The 
amino-terminus of MCL-1 also regulates its association with mitochondrial membranes; 
however, the underlying mechanism is unclear (Germain and Duronio, 2007).  
Additionally, several reports claim that MCL-1 is localized both to the mitochondria and 
the nucleus, where it interacts with PCNA and inhibits cells from progressing through S-
phase (Fujise et al., 2000).  
 
 
MCL-1 Anti-apoptotic Function 
 
In-vitro binding assays with recombinant anti-apoptotic BCL-2 family members 
and peptides corresponding to the BH3 domains of pro-apoptotic molecules demonstrate 
that MCL-1 selectively binds pro-apoptotic family members (Chen et al., 2005b).  MCL-
1 displays selective binding for pro-apoptotic molecules BIM, PUMA, NOXA, and BAK 
but does not interact with BAD (Chen et al., 2005b; Opferman et al., 2003).  
Interestingly, in-vitro competitive binding assays indicate that MCL-1 and A1 are the 
only anti-apoptotic family members with the ability to interact with NOXA (Chen et al., 
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2005b).  Moreover, BAK selectively interacts with MCL-1 and BCL-X but not BCL-2 
(Chen et al., 2005b). The interaction between MCL-1 and BAK has also been confirmed 
by co-immunoprecipitation of proteins derived from mitochondria (Willis et al., 2005).  
Another report indicated that MCL-1 interacts with BAX, where it protects hematopoietic 
cells from apoptosis under a variety of death stimuli including etoposide, UV irradiation, 
and growth factor withdrawal (Zhou et al., 1997). 
 
 
MCL-1 and Cell Survival 
 
BCL-2 family members play specific roles in regulating homeostasis during 
various stages of hematopoiesis (Fig. 1.3). The roles of anti-apoptotic BCL-2 family 
members during hematopoiesis have been identified through loss of function studies.   
Bcl-2-deletion results in viable mice that display an increase in apoptosis of mature B and 
T lymphocytes after 3 weeks of age (Veis et al., 1993). Bcl-XL-deficient embryos die at 
embryonic day 13 due to neuronal and erythroid defects (Motoyama et al., 1995).   
Conditional deletion of Bcl-XL in the erythroid lineage results in severe anemia and 
reduces the number of red blood cells significantly, indicating that BCL-XL is important 
during erythropoiesis (Wagner et al., 2000). 
 
MCL-1 is unique among pro-survival BCL-2 molecules in that it is essential for 
early (E3.5) embryonic development and also has a critical role during multiple stages of 
hematopoiesis and lymphopoiesis (Rinkenberger et al., 2000) (Fig. 1.3).  Conditional 
deletion of Mcl-1 during early thymocyte development, using Lck-Cre, results in no 
viable, mature, deleted T cells (Opferman et al., 2003).  Additionally, deletion of Mcl-1 
during early B cell development, using CD19-Cre, results in death at the pro-B stage 
(Opferman et al., 2003).  This suggests that MCL-1 is critical for the development of 
lymphocytes.  Furthermore, MCL-1 is also required for the maintenance of mature 
lymphocytes (Dzhagalov et al., 2008; Opferman et al., 2003).   
  
MCL-1 is also essential during the early stages of hematopoiesis (Fig. 1.3).  
Inducible deletion of Mcl-1 in hematopoietic lineages results in rapid hematopoietic 
failure (Opferman et al., 2005).  The earliest populations lost are the hematopoietic stem 
cells (HSCs), common myeloid progenitors (CMPs), and common lymphoid progenitors 
(CLPs) (Opferman et al., 2005).  Moreover, during myelopoiesis, MCL-1 is required for 
the differentiation of granulocyte precursors to mature neutrophils (Dzhagalov et al., 
2007; Steimer et al., 2009).  In contrast, deletion of Mcl-1 in the myeloid lineage does not 
block the development of mature macrophages but is important for survival during 
effector function (Dzhagalov et al., 2007; Steimer et al., 2009).  These data underscore an 
essential role for MCL-1 in promoting the survival and differentiation of many 
hematopoietic lineages. 
  
In addition to hematopoiesis, MCL-1 is also required during the development of 
the central nervous system (CNS) (Arbour et al., 2008).  Conditional deletion of Mcl-1 in 
the forebrain results in embryonic lethality at day 15, whereas, deleting Mcl-1 earlier in 
CNS development results in lethality at embryonic day 12.5 (Arbour et al., 2008). 
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Figure 1.3. Apoptotic Checkpoints during Hematopoiesis 
All blood cell lineages arise from a hematopoietic stem cell (HSC) that is capable of self-
renewal and has an indefinite life-span.  HSCs give rise to multi-potent progenitors 
(MPPs) which still retain the ability to give rise to all blood cell lineages, but lack long-
term self-renewal capacity.  MPPs can produce two progenitors, common myeloid 
progenitors (CMPs) and common lymphoid progenitors (CLPs).  CLPs can produce the 
lymphoid lineages (B, T, and perhaps NK cells).  CMPs produce at least two other 
oligopotent progenitor populations, the megakaryocyte erythroid progenitor (MEP) that 
produce red blood cells (erythrocytes), megakaryocytes (generates platelets), and the 
granulocyte monocyte progenitor (GMP), which produces neutrophils and macrophages.  
Listed beside each differentiation step or progenitor population are the known anti-
apoptotic regulators that promote the survival of the given population.  Anti-apoptotic 
MCL-1 has multiple checkpoints as has been illustrated to be critical for the survival of 
several multipotent and oligopotent progenitor populations (HSC, CMP, CLP, and GMP) 
and has been shown to be critical for the differentiation of granulocytes, but interestingly 
not the monocyte lineage.  A1-A, a murine ortholog of BFL-1, has also been shown to 
play an important role in promoting neutrophil survival in response to stress, but is not 
absolutely required for survival (indicated by open arrowhead).  In the erythroid lineage, 
BCL-XL is the essential survival molecule, but unpublished data indicates that MCL-1 
may also play an essential role during early differentiation.  In the megakaryocytic 
lineage it appears that while neither MCL-1 nor BCL-XL is solely responsible for 
survival, the two pro-survival molecules appear to have overlapping functions (indicated 
by open arrowheads) in promoting megakaryocyte survival.  The critical anti-apoptotic 
regulators of some lineages including NK cells are still uncertain.  
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CLPCMP
B cell T cellMonocyte
GMP
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MCL-1 Regulation 
 
Mcl-1 is regulated at the transcriptional, translational, and post-translational 
levels.  Growth factors and cytokines including interleukin-2 (IL-2), interleukin-7 (IL-7), 
and granulocyte-macrophage colony-stimulating factor (GM-CSF) induce Mcl-1 
transcription (Opferman et al., 2005; Opferman et al., 2003; Wang et al., 1999). 
Likewise, a variety of signaling pathways including MAP kinases, PI3K/Akt, and 
JAK/STAT modulate elements in Mcl-1’s promoter to increase transcription (Huang et 
al., 2000; Wang et al., 1999).  In addition, Mcl-1 mRNA translation is regulated by 
mTORC1 (Mills PNAS 2008).  
 
 MCL-1 protein expression is tightly regulated at the post-translational level.  
MCL-1 phosphorylation in response to cellular signaling is a critical control point for 
regulating its anti-apoptotic function.  However, there is evidence of phosphorylation 
both promoting and inhibiting MCL-1 anti-apoptotic activity depending on the type of 
death stimuli.  For example, oxidative stress promotes JNK-mediated phosphorylation of 
human MCL-1 at two residues (Ser-121 and Thr-163) resulting in a loss of anti-apoptotic 
function (Inoshita et al., 2002).  In contrast, phosphorylation at the same residue (Thr-
163) blocks ubiquitinylation, thus, extending the protein half-life and cellular survival 
(Domina et al., 2000; Li et al., 2007).  MCL-1 phosphorylation is also potently regulated 
by growth factor availability.  For example, cytokine withdrawal results in 
phosphorylation of MCL-1 on Ser-159 by GSK-3 thereby facilitating its degradation 
(Maurer et al., 2006).   
 
 The short half-life (~2 hours) of MCL-1 distinguishes it from other anti-apoptotic 
BCL-2 family members; the amino-terminus possess several proline-glutamic acid-
serine-threonine (PEST) regions, a common feature of rapidly degraded proteins.  
Nevertheless, the PEST regions are dispensable for MCL-1 protein turnover (Akgul et al., 
2000).  MCL-1 undergoes both ubiquitin-dependent and ubiquitin-independent 
degradation (Stewart et al., 2010a; Zhong et al., 2005).  Three E3 ligases have been 
implicated in MCL-1 ubiquitinylation.  The HECT-domain containing MULE targets 
MCL-1 for degradation by the proteosome (Zhong et al., 2005).  Whether MULE-
dependent ubiquitinylation of MCL-1 occurs in healthy cells or apoptotic cells remains 
controversial (Hao et al., 2012; Zhong et al., 2005).  Both ß-TRCP and FBW7 are SKP1-
cullin-1-F-box (SCF) complex E3 ligases that ubiquitinylate MCL-1 in a 
phosphorylation-dependent manner (Ding et al., 2007; Inuzuka et al., 2011).  
Furthermore, the deubiquitinase, USP9X, binds to MCL-1 and removes polyubiquitin 
chains, thus, stabilizing MCL-1 protein levels (Schwickart et al., 2010). 
 
 
MCL-1 and Cancer 
 
Dysregulated MCL-1 expression can inappropriately promote cell survival.  For 
example, transgenic expression of MCL-1 in mice can lead to tumorigenesis and 
hyperplasia (Matsushita et al., 2003; Zhou et al., 2001).  MCL-1 is overexpressed and 
often associated with chemotherapeutic resistance in many different cancers including 
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acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic 
myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and multiple 
myeloma, (Kaufmann et al., 1998; Pepper et al., 2008; Wei et al., 2006).   In addition, 
MCL-1 is upregulated in a variety of solid tumors including hepatocellular carcinoma, 
pancreatic cancer, testicular cancer, cervical cancer, lung cancer, and melanoma (Chung 
et al., 2002; Sano et al., 2005; Sieghart et al., 2006; Song et al., 2005; Zhuang et al., 
2007).  Furthermore, the MCL-1 locus is frequently amplified in human cancers 
(Beroukhim et al., 2010). The expanding variety of malignancies that display high levels 
of MCL-1 expression illustrate the importance of understanding how MCL-1 expression 
and function are regulated.   
 
Cancer cells often violate a number of cellular checkpoints including cell cycle 
arrest and the induction of apoptosis. For that reason, they often become dependent on 
anti-apoptotic molecules to bypass programmed cell death (Certo et al., 2006).  As a 
result, small molecules that antagonize these pro-survival molecules have been developed 
as a therapeutic approach.  ABT-737 is a small molecule that inhibits BCL-2 and BCL-
XL and promotes cell death.  However, high levels of MCL-1 can contribute to resistance 
to ABT-737 (Certo et al., 2006).  Consequently there has been much effort to find a small 
molecule that is capable of blocking the protective effects of MCL-1(Nguyen et al., 
2007).  
 
Dynamic Structure of Mitochondria 
 
Mitochondria are dynamic organelles constantly undergoing fission and fusion to 
maintain a cellular network important for their function (Detmer and Chan, 2007) (Fig. 
1.4). Under normal conditions, fission and fusion are balanced to support normal 
mitochondrial morphology; however, the disturbance of this equilibrium leads to 
dramatic alterations in their shape.  For example, increases in fusion result in elongated 
mitochondria that are extremely interconnected (Smirnova et al., 2001) (Fig. 1.5).  
Conversely, cells with a high fission rate produce many small, fragmented mitochondria 
(Chen et al., 2003) (Fig. 1.5).   
 
 
Internal Structure of Mitochondria 
 
Mitochondria possess a selectively-permeable outer membrane and an inner 
membrane consisting of a larger surface area that folds and forms invaginations called 
cristae (Frey and Mannella, 2000).  The two membranes surround two aqueous spaces, 
the matrix, where the TCA cycle enzymes and mitochondrial genome are located, and the 
intermembrane space, where cytochrome c, resides.  Recent advances in electron 
microscopy techniques have revealed that the mitochondrial inner membrane can be 
subdivided into distinct domains: the inner boundary membrane, the cristae membrane, 
and the cristae junctions (Frey and Mannella, 2000) (Fig. 1.6).  The inner boundary 
membrane consists of the areas where the inner membrane juxtaposes to the outer 
membrane; whereas the cristae membrane entwines and extends, increasing the surface 
area of the inner membrane (Mannella, 2006).  The cristae junctions are constricted 
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Figure 1.4. Mitochondrial Dynamics 
Mitochondrial fusion and fission control mitochondrial number and size. With fusion, 
two mitochondria become a single larger mitochondrion with continuous outer and inner 
membranes. Conversely, a single mitochondrion can divide into two distinct 
mitochondria by fission.  Reprinted by permission from Macmillan Publishers Ltd: 
Detmer, S.A., and Chan, D.C. (2007). Functions and dysfunctions of mitochondrial 
dynamics. Nat Rev Mol Cell Biol 8, 870-879. 
Figure 1.5. Mitochondrial Morphology 
Mitochondrial length, size and connectivity are determined by the relative rates of 
mitochondrial fusion and fission. In wild-type cells (shown in the central panel), 
mitochondria form tubules of variable length. In the absence of mitochondrial fusion (for 
example, in mitofusin (Mfn)-null cells (shown in the left panel), which lack MFN1 and 
MFN2), unopposed fission results in a population of mitochondria that are all 
fragmented. Conversely, decreased fission relative to fusion, for example, in DRP1 K38A 
cells (shown in the right panel), which have a dominant-negative form of dynamin-
related protein-1 (DRP1), results in elongated and highly interconnected mitochondria. 
Scale bar represents 10 μm.  Reprinted by permission from Macmillan Publishers Ltd: 
Detmer, S.A., and Chan, D.C. (2007). Functions and dysfunctions of mitochondrial 
dynamics. Nat Rev Mol Cell Biol 8, 870-879. 
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Figure 1.6. Mitochondrial Ultrastructure 
The diagram indicates the different regions of the inner membrane. CJ, cristae junction; 
CM, cristae membrane; IBM, inner boundary membrane; IM, inner membrane; IMS, 
intermembrane space; OM, outer membrane.  Reprinted by permission from Macmillan 
Publishers Ltd: Detmer, S.A., and Chan, D.C. (2007). Functions and dysfunctions of 
mitochondrial dynamics. Nat Rev Mol Cell Biol 8, 870-879. 
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constricted regions that separate the inner membrane boundary from the cristae 
membrane (Mannella, 2006) (Fig. 1.6).  Furthermore, immunoelectron microscopy has 
determined that proteins are differentially distributed among the different domains.  For 
example, translocase of inner membrane proteins are localized to the inner boundary 
membrane whereas proteins of the respiratory complexes are localized to the cristae 
membranes (Vogel et al., 2006). 
 
 
Regulators of Fusion and Fission 
 
The major mediators of mitochondrial fission and fusion are evolutionarily 
conserved and consist of proteins from the dynamin family of GTPases (Okamoto and 
Shaw, 2005).  Mitochondrial fusion incorporates fusion of both the outer and inner 
mitochondrial membranes.  In mammalian cells, the early steps of mitochondrial fusion 
are regulated by Mitofusins, which are GTPases that reside on the outer mitochondrial 
membrane (Chen et al., 2003).  There are two mitofusin homologues, Mitofusin 1 (Mfn1) 
and Mitofusin 2 (Mfn2), which have similar roles in mitochondrial fusion.  Both Mfn1 
and Mfn2 engage in homotypic interactions on adjacent mitochondria and through GTP 
hydrolysis bring the two mitochondria together (Koshiba et al., 2004). Cells that are 
deficient in both Mfn1 and Mfn2 have dramatically reduced levels of mitochondrial 
fusion (Chen et al., 2005a; Chen et al., 2003).  Together with the mitofusins, OPA1 is 
another dynamin family GTPase that is critical for mitochondrial fusion.  OPA1 localizes 
to the inner mitochondrial membrane and intermembrane space and is crucial for fusion 
of the inner mitochondrial membrane (Griparic et al., 2004).  The OPA1 gene undergoes 
alternative splicing to produce eight mRNA isoforms (Delettre et al., 2001).  
Additionally, OPA1 is proteolytically cleaved into additional isoforms that are necessary 
for mitochondrial fusion (Ishihara et al., 2006). 
 
 Drp1 is the member of the dynamin family of GTPases that regulates the 
opposing process of mitochondrial fission in mammalian cells.  Drp1 localizes both to the 
cytosol and to the mitochondrial outer membrane (Smirnova et al., 2001).  Drp1 forms 
oligomers around the mitochondrion, constricts it and utilizes GTP hydrolysis to drive 
mitochondrial division (Praefcke and McMahon, 2004).  Expression of a dominant-
negative Drp1 in cells results in inhibition of endogenous Drp1 and excessive 
mitochondrial elongation (Lee et al., 2004; Smirnova et al., 2001).  Based on these 
results, mitochondrial morphology is a highly dynamic process that is regulated by the 
opposing processes of fission and fusion. 
 
 
Biological Functions 
 
Perhaps the most important biological consequence of fission and fusion is 
maintenance of a healthy mitochondrial population.  Mitochondria produce a substantial 
amount of reactive oxygen species (ROS); therefore, their genome is remarkably 
susceptible to DNA damage.  Mitochondria protect themselves from accumulating 
excessive damage through fusion, which facilitates the exchange of lipid membranes and 
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the mitochondrial genome between organelles thereby allowing damaged mitochondria to 
be restored to normal. Whereas, fission is necessary to increase mitochondrial number 
and allow distribution to daughter cells during cell division (Chen and Chan, 2005; Mitra 
et al., 2009).  Imbalances in fission and fusion lead to a variety of cellular and 
mitochondrial defects (Bleazard et al., 1999; Chen et al., 2003).  For example, normal 
mitochondrial fusion is required for cell growth, efficient oxidative phosphorylation and 
ATP production (Chen et al., 2005a).  Thus, the integrity of the mitochondrial network is 
intimately associated with cellular fate and bioenergetics. 
 
 
The BCL-2 Family and Dynamics 
 
In addition to their role in apoptosis, BCL-2 family proteins have also been shown 
to regulate mitochondrial dynamics (Autret and Martin, 2009).  However, the 
mechanisms and functional impact through which individual BCL-2 proteins influence 
mitochondrial dynamics remains elusive, as in some cases the same molecules can 
promote both fission and fusion of the mitochondrial network.  For example, the 
expression of anti-apoptotic BCL-XL in various cell types promoted mitochondrial fusion 
and interacted with Mfn2 (Delivani et al., 2006).  In cortical neurons, BCL-XL expression 
increased both fission and fusion (Berman et al., 2009).  Additionally, when over-
expressed, the pro-apoptotic effectors BAX and BAK induced mitochondrial fission 
(Sheridan et al., 2008); however, Bax and Bak doubly-deficient cells also exhibited a 
fragmented mitochondrial network and had decreased rates of mitochondrial fusion 
(Karbowski et al., 2006).  In a cell free system used to study mitochondrial fusion, the 
addition of recombinant BAX promoted fusion in an Mfn2-dependent manner (Hoppins 
et al., 2011b).  The fusogenic function of BAX was limited to its monomeric form as 
oligomeric BAX abrogated its ability to promote fusion (Hoppins et al., 2011a).     
Direct interaction between Mfn2 and some of the BCL-2 family members, such as BCL-
XL and BAX, mechanistically demonstrates how BCL-2 proteins regulate mitochondrial 
dynamics.  To better clarify their role, it is important to separate the apoptotic functions 
of the BCL-2 family members from their ability to regulate mitochondrial 
morphogenesis. 
   
 It is significant to note that the process of mitochondrial fission and fusion has 
also been shown to play a role in apoptosis.  Studies have demonstrated that 
mitochondrial fragmentation can occur early during apoptosis (Frank et al., 2001).  To 
what extent the fission machinery directly regulates apoptosis is still unclear.  For 
example, the amount of mitochondrial fragmentation during apoptosis was shown to 
depend on Drp1, while reduced Drp1 expression reduced cytochrome c release 
(Breckenridge et al., 2003; Frank et al., 2001).  However, other studies found that Drp1 
inhibition did not affect cell death (Estaquier and Arnoult, 2007; Sheridan et al., 2008).  
The role mitochondrial fusion may play in apoptosis is also not well understood.  Some 
evidence has suggested that inhibition of Mfn1- and Mfn2-induced mitochondrial 
fragmentation and sensitized cells to death-inducing agents (Jahani-Asl et al., 2007; 
Sugioka et al., 2004).  Overexpression of Mfn2 delayed BAX activation and the release 
of cytochrome c (Neuspiel et al., 2005).  Likewise, increased Mfn2 expression protected 
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neurons from apoptotic stimuli (Jahani-Asl et al., 2007).  The link between regulators of 
inner mitochondrial membrane fusion and apoptosis has also been investigated.  OPA1 
expression was able to protect cells from cell death induced through the mitochondrial 
pathway (Frezza et al., 2006).  In contrast another study found that expression of Mfn1, 
Mfn2, or OPA1 had no protective effect on cell death and that cytochrome c release 
occurs in mitochondria with a reticular network (Sheridan et al., 2008).   
 
 
Supermolecular Protein Complexes in the Inner Mitochondrial Membrane 
 
In addition to being the critical organelle at which the commitment to intrinsic 
apoptosis is made, mitochondria are also important for the production of energy by 
oxidative phosphorylation.  This process includes electron transport chain complexes that 
pass electrons generated from the Krebs cycle in a stepwise method to reduce molecular 
oxygen and produce water. Protons are simultaneously pumped out of the mitochondrial 
matrix and into the cytosol generating an electrochemical gradient across the 
mitochondrial inner membrane (Mitchell, 1961) (Fig. 1.7).  The protons then diffuse back 
into the mitochondria through the F1F0-ATP synthase to generate ATP from ADP 
(Wallace, 1999) (Fig. 1.7).  The complexes of the electron transport chain are massive, 
multi-subunit complexes and consist of NADH dehydrogenase (complex I), succinate 
dehydrogenase (complex II), ubiquinone oxidoreductase (complex III), and cytochrome c 
oxidase (complex IV) (Fig. 1.7).  To increase the efficiency of oxidative phosphorylation, 
the inner membrane is folded to generate cristae, which amplifies the enzymes 
participating in this metabolic process. 
 
 
Respiratory Supercomplexes 
 
The structural organization of the respiratory chain complexes I-IV have 
historically included the lateral diffusion of the individual complexes in the inner 
membrane, where electron transfer depends on the transient collision of these complexes 
(Lenaz and Genova, 2007) (Fig. 1.7).  However, more recently blue-native gel 
electrophoresis (BN-PAGE) has revealed that these complexes are organized into 
megadalton supramolecular complexes, called supercomplexes.  These supercomplexes 
are assemblies of the different respiratory components and are capable of respiration 
(Acin-Perez et al., 2008) (Fig. 1.8).  Additionally, genetic mutations encoding one 
subunit of a complex result in the de-stabilization of other complexes (Acin-Perez et al., 
2008).  Likewise, the stability of the supercomplexes also depends on cardiolipin, an 
abundant phospholipid in the IMM (Pfeiffer et al., 2003). It is hypothesized that the 
formation of respiratory supercomplexes increases the efficiency of electron transfer 
between the complexes; therefore, reducing the generation of unstable reactive oxygen 
radicals. 
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Figure 1.7. Oxidative Phosphorylation 
Electrons derived from the Krebs cycle are passed through the electron transport 
complexes to reduce oxygen to water.  Simultaneously, protons are pumped out of the 
mitochondrial matrix, generating an electrochemical gradient.  Protons then diffuse back 
into the matrix through the F1F0-ATP synthase, producing the energy required to make 
ATP from ADP.  Reprinted by permission from Macmillan Publishers Ltd:  Acin-Perez, 
R., Fernandez-Silva, P., Peleato, M.L., Perez-Martos, A., and Enriquez, J.A. (2008). 
Respiratory active mitochondrial supercomplexes. Mol Cell 32, 529-539. 
Figure 1.8. Respiratory Supercomplexes 
Model for the organization of different subtypes of respiratory supercomplexes.  The 
respiratory complexes are assembled into supercomplexes of various types.  Reprinted by 
permission from Macmillan Publishers Ltd:  Acin-Perez, R., Fernandez-Silva, P., Peleato, 
M.L., Perez-Martos, A., and Enriquez, J.A. (2008). Respiratory active mitochondrial 
supercomplexes. Mol Cell 32, 529-539. 
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F1F0-ATP Synthase Dimers and Oligomers 
 
The F1-F0-ATP synthase (ATP synthase) is composed of a soluble catalytic unit, 
F1, located inside the mitochondrial matrix, and a membrane-bound unit, F0, which 
anchors the enzyme in the inner membrane and mediates the flow of protons through the 
membrane.  ATP synthase exists in monomers but also forms supercomplexes containing 
homo-dimers and homo-oligomers (Schagger and Pfeiffer, 2000).  The ATP synthase 
dimers and  oligomers are necessary for generation of mitochondrial cristae and increase 
the efficiency of ATP production (Paumard et al., 2002; Strauss et al., 2008).  The 
dimerization of ATP synthase predominantly involves the F0 domains but also includes 
the F1 domains.  The F0 domains are closely assembled, whereas the F1 have a distant 
association.  This arrangement produces a 40º angle between the monomers, curving the 
lipid membrane, which is thought to be responsible for the structure of the cristae 
(Minauro-Sanmiguel et al., 2005).  In yeast, deletion of F0 subunits e and g abolish 
dimerization and lead to cristae morphology abnormalities (Paumard et al., 2002).  The F1 
regions of each monomer are indirectly associated by inhibitory factor 1 (IF1), which 
connects the two monomers (Cabezon et al., 2003). 
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CHAPTER 2.    MATERIALS AND EXPERIMENTAL PROCEDURES* 
 
 
Cells and Cell Culture 
 
 SV40-transformed wild-type (wt) and Mcl-1-deficient mouse embryonic 
fibroblasts (MEFs) have been previously described (Opferman et al., 2003).  Mcl-1f/f 
Rosa-ERCreT2 and wt Rosa-ERCreT2 MEFs were generated from E12.5 embryos and 
SV40-transformed. To induce Mcl-1-deletion, the MEFs were treated for 48 hours with 
100 nM (4-hydroxy)-tamoxifen (Sigma) in culture media to induce Cre expression.  
HEK293T cells and human non-small cell lung cancer (NSCLC) cells were obtained 
from American Type Culture Collection. All cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) supplemented with 5% fetal bovine serum, 20mM 
L-glutamine (Gibco) and 10mM HEPES (Gibco).  Cells grown in galactose were grown 
in glucose-free Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented 
with 10% fetal bovine serum, 2mM glutamine, and 10mM galactose. 
 
 
Plasmids, Expression Constructs, and Generation of Mutants 
 
All Mcl-1 constructs were developed using mouse Mcl-1 cDNA.  The mutant 
Mcl-1OM, in which arginines 5 and 6 were replaced by alanines, was generated by site-
directed mutagenesis (Stratagene). The N-terminal 67 amino acids of MCL-1 (MCL-1?N) 
and the C-terminal 22 amino acids (MCL-1?C) were deleted by polymerase chain reaction 
(PCR).  The MCL-1-hBCL-2 chimera was made by fusing the N-terminal 50 amino acids 
of MCL-1 to full-length human BCL-2 by PCR. The mutant Mcl-1Matrix was generated by 
fusing amino acids 1-58 of N. crassa ATP-synthase to Mcl-1?N. Mitochondrial 
morphology and fusion were measured using matrix-localized photoactivatable-GFP 
(Karbowski et al., 2004) and Mito-DsRed (Clontech).  MCL-1?ATG1 was generated by 
PCR amplification using 5' -cgagctcgaattctagtttggcctgcggagaaac -3' (sense) and 5'- 
gcatatctaataagataggcgggcggatccgca - 3' (antisense).  The non-canonical mRNA splicing 
mutant Mcl-1SD;SAmut was generated by mutating nucleotide 52 from G to A changing the 
amino acid sequence from glycine to serine and mutating nucleotide 189 from G to T 
creating a silent mutation and maintaining the amino acid valine (Kojima et al., 2010).  
The PCR primers for nucleotide 52 are forward primer (5’- 
aacctgtactgcggcagcgccagcctcggcgcg-3’) and reverse primer (5’- 
cgcgccgaggctggcgctgccgcagtacaggtt-3); and for nucleotide 189 are forward primer (5’-
cccggccgccgcccgttggcgccgaggaccccg-3’) and reverse primer (5’-
cggggtcctcggcgccaacgggcggcggccggg-3’). 
 
 
* Reprinted with permission. Perciavalle, R.M., Stewart, D.P., Koss, B., Lynch, J., 
Milasta, S., Bathina, M., Temirov, J., Cleland, M.M., Pelletier, S., Schuetz, J.D., et al. 
(2012). Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples 
mitochondrial fusion to respiration. Nature Cell Biology 14, 575-583. 
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Ecotropic Retroviral Production and Cell Transduction 
 
Ecotropic retroviruses were produced by co-transfection of retroviral expression 
plasmids in 293T cells with packaging plasmids (pMD-old-Gag-Pol and pCAG4-Eco) 
using FuGene6 (Roche Applied Bioscience). 
 
 
Western Blotting, Co-immunoprecipitation, and Antibodies 
 
For immunoblot analysis, cells were lysed in Flag Lysis Buffer (50mM Tris-HCl 
pH 7.4, 150mM NaCl, 1% TritonX-100, 1mM EDTA) containing complete protease 
inhibitors (Roche) on ice for 30 minutes. Whole cell lysates (WCL) were cleared by 
centrifugation and protein concentrations were determined by BCA assay. For co-
immunoprecipitation studies, whole cell lysates (WCLs) were pre-cleared and then 
coupled with both anti-BIM short and anti-BIM long rat monoclonal antibodies 
(Millipore) or rat IgG (Santa Cruz Biotechnology) for 1 hour then precipitated with 
protein A/G-plus agarose (Santa Cruz Biotechnology).  Immunocomplexes were 
recovered, washed, and resuspended in sample buffer.  Immunocomplexes and post-
immunoprecipitated supernatants were subjected to electrophoresis using Bis-Tris gels 
(Invitrogen), transferred to PVDF (Millipore) and developed using Western Lightning 
(Perkin Elmer). The following antibodies were used: anti-MCL-1 (Rockland 
Immunochemical), anti-BIM (BD Biosciences), anti-Tim50 (Abcam), anti-Tom40 (Santa 
Cruz), anti-Prohibitin1 (Abcam), anti-Opa1 (BD Biosciences), anti-MnSOD (BD 
Biosciences), anti-PDI (BD Biosciences), anti-hBCL-2 (Clone 6C8, gift of S. 
Korsmeyer), anti-mBCL-2 (Clone 3F11, gift of S. Korsmeyer), anti-Complex II subunit 
70 (MitoSciences), anti-Complex IV subunit II (Mitosciences), anti-Complex I subunit 
NDUFA9 (MitoSciences), anti-Pyruvate dehydrogenase (Cell Signaling) and anti-Actin 
mouse monoclonal (Millipore), Complex I, anti-NDUFA9 (Molecular Probes); Complex 
II, anti-Fp70 (Molecular Probes); Complex III, anti-Core 2 (Molecular Probes); Complex 
IV, anti-Cox I (Molecular Probes); ATP Synthase, anti-5A1 (Proteintech Group); ATP 
Synthase, anti-5B (Santa Cruz Biotechnology); ATP Synthase, anti-gamma (GeneTex);  
ATP Synthase, anti-OSCP (Santa Cruz Biotechnology). 
 
 
Cell Death Experiments 
 
Both wt Mcl-1 Rosa-ERCreT2 MEFs and Mcl-1f/f Rosa-ERCreT2 MEFs stably 
expressing murine stem cell virus (MSCV)-puro vector, wt MCL-1, MCL-1OM, MCL-
1Matrix, or hBCL-2 were treated with tamoxifen for 48 hours and treated with etoposide or 
staurosporine (Calbiochem). Cell viability was determined by staining with Annexin-V-
FITC and propidium iodide (PI) (BD Biosciences) and flow cytometry (FACSCalibur, 
BD Biosciences). 
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RNAi Experiments 
 
For RNA-mediated interference (RNAi), MEFs were plated in Opti-MEM media 
(Invitrogen) and transfected with respective 70 nM Stealth siRNAs (Invitrogen) specific 
for mouse Tom40 and Tim50 using Lipofectamine RNAi-Max (Invitrogen). Six hours 
after transfection media was replaced with complete DMEM media. Seventy-two hours 
after transfection cells were collected, lysed and immunoblotted. Stealth siRNA 
sequences were: TOM40: ACUGAACAACUGGUUGGCUACAGUA, 
CCCUCUGUAUGAAAUAGUCAUCUUC, 
GAAGAUGACUAUUUCAUACAGAGGG; TIM50: 
GCCCUACUACCAGCCACCUUAUACA, 
UGUAUAAGGUGGCUGGUAGUAGGGC, 
UCAAGACCAUUGCACUGAACCAAGU 
 
 
Measurement of Superoxide Anion 
 
MitoSOX-red (Invitrogen) was used to measure reactive oxygen species (ROS) in 
SV40-transformed wt Mcl-1 Rosa-ERCreT2 MEFs and Mcl-1f/f Rosa-ERCreT2 MEFs 
expressing MSCV-puro vector, wt MCL-1, MCL-1OM, MCL-1Matrix, and hBCL-2. Cells 
were treated with 5μM MitoSOX for 30 minutes. at 37°C and fluorescence measured by 
flow cytometry.  Antimycin A (Sigma) (10 nM), which induces superoxide through the 
inhibition of complex III, was used as a positive control. 
 
 
Isolation and Purification of Mouse Liver Mitochondria 
 
Mouse livers were homogenized in Mito Isolation Buffer (MIB) buffer (200mM 
Manitol, 68mM Sucrose, 10mM Hepes-KOH pH 7.4, 10mM KCl, 1mM EDTA, 1mM 
EGTA. 0.1% BSA).  Mitochondria were isolated using differential centrifugation and 
were purified using a Percoll-gradient consisting of 70% percoll, overlayed by 30% 
Percoll (Pierce) in 5mM MOPS and 0.3M mannitol.  Protein content was determined by 
Bradford assay (BioRad). 
 
 
Subcellular Fractionation and Isolation of Heavy Membrane from Cells 
 
Cells were swollen in 220mM Mannitol, 70mM Sucrose, 10mM Hepes-KOH (pH 
7.4) for 30 minutes on ice.  Cells were homogenized 30 times with a 30 gauge needle.  
The non-lysed cells and nuclei were sedimented by centrifugation at 600xg for 10 
minutes and disposed.  The supernatant was centrifuged at 5,500xg for 15 minutes and 
the pellet was the heavy membrane fraction.  The supernatant was centrifuged at 
100,000xg for 30 minutes and the soluble fraction contains the purified cytosolic fraction. 
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Proteolysis of Heavy Membrane Fraction 
 
The heavy membrane (HM) fraction was isolated from cells or mouse liver and 
protein concentration determined by Bradford assay.  HM (40ug) were treated with the 
following treatments: proteinase K (0.2mg/ml), 20mM KCl (osmotic shock), 1% SDS 
(membrane solubilization) for 30 minutes on ice. Proteins were precipitated with 
tricholoroacetic acid (Sigma). 
 
 
Oxygen Consumption 
 
Respiration was measured in intact cells (64,000/well) seeded in poly-L-lysine-
coated plates using the XF24 analyzer (Seahorse Bioscience) (Ferrick et al., 2008).  After 
5 hours, the cells were loaded into the machine to determine the oxygen consumption rate 
(OCR). Respiration was measured sequentially after addition of 0.5μM oligomycin, 
0.5μM FCCP, and 0.5μM rotenone. After each injection, OCR was measured (3 
minutes), the medium mixed (2 minutes), and measured (3 minutes). 
 
 
Alkali Wash 
 
Purified mouse liver mitochondria were sonicated (40W for 15 seconds, twice) on 
ice and then centrifuged at 10,000xg for 10 minutes to remove intact mitochondria.  The 
supernatant was centrifuged at 100,000xg for 30 minutes and the supernatant is the 
soluble fraction.  The pellet was treated with 0.1M sodium carbonate (pH 11.5) in MIB 
buffer for 30 minutes on ice and then centrifuged at 100,000xg for 30 minutes and 
supernatant and pellet collected. 
 
 
Mitochondria Subfractionation 
 
Mitochondria were swollen on ice for 30 minutes in 14 ml of 10mM KH2PO4 (pH 
7.4).  One-third volume of 1.8M sucrose, 10mM MgCl2 was added on ice for 30 minutes 
to shrink the mitochondria.  Mitochondria were sonicated (4 Amps for 5 seconds) in 2.5 
ml aliquots then centrifuged at 12,000xg for 10 minutes to get supernatant 1 and pellet 1.   
Supernatant 1 was then spun at 100,000xg for 1 hour and the pellet 2 is the OM.  Pellet 1 
was resuspended in 7ml of 1.8M sucrose, 10mM MgCl2 on ice for 5 minutes and 
centrifuged at 5,500xg for 15 minutes and pellet 3 is the mitoplast. 
 
 
Cellular ATP 
 
ATP assays were performed using the ATP Bioluminescence Assay Kit HSII 
(Roche) following the manufacturer’s instructions. Briefly, cells were counted in 
triplicate and washed in PBS.  Cells (0.5 x 106/ml) were resuspended in lysis buffer (5 
minutes ??????????Lysed cells were incubated at 100?? for 2 minutes, centrifuged at 
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10,000xg for 5 minutes.  Cell lysates (50 ?l ) were diluted in 50?l of dilution buffer, and 
100μl of luciferase reagent was added. The luminescence was measured using a 
Luminometer (Biotek Synergy) and ATP concentration was determined by comparing 
values to a standard curve. 
 
 
Mitochondrial Fusion Assay and Image Analysis 
 
Cells were grown in 4-well chambers and were transiently-transfected using 
Fugene6 with a photoactivatable-GFP targeted to the mitochondrial matrix (Karbowski et 
al., 2004). Images were captured using a Marianas spinning disk confocal (SDC) imaging 
system consisting of a Zeiss Axio Observer (Carl Zeiss MicroImaging) inverted 
microscope with motorized XYZ stage, a CSU-X confocal head (Yokogawa Electric 
Corporation), LaserStack laser launch and Vector laser scanner head (Intelligent Imaging 
Innovations-3i). Images were collected using a Zeiss Plan-Apochromat 63x 1.4 NA oil 
objective and Evolve 512 EMCCD camera (Photometrics). 3-D time-lapse images of the 
cells were acquired from the top to the bottom of mitochondria with 0.4μm z-sections 
with varying time-intervals (10 initial frames at every 2 minutes, and at every 5 minutes 
after that for total of 2-3 hr).  A small region of interest (~2?m) of the mitochondria was 
activated in the third time-frame using 405 nm laser at two middle planes of 3-D 
acquisition.  The fluorescence intensity was measured using Slidebook (Intelligent 
Imaging Innovations-3i).  The maximum intensity projections (MIP) of the z-stacks for 
each time point were created. The activated mitochondria were masked by thresholding 
the pixel intensities above the background.  The total area of intensity (all pixels above 
threshold) was normalized to the post-activation time point and plotted over time.  
 
 
Analysis of Mitochondrial Morphology and Shape 
 
Cells were grown in 4-well chambers and were transiently transfected using 
Fugene6 with mito-DsRed (Clontech). Images were captured using a Marianas spinning 
disk confocal (SDC) imaging system using a 63X 1.4 NA Apochromat objective (Zeiss).  
Images were acquired from the top to the bottom of the mitochondria in 0.4?m z-
sections.  For morphological analysis, the fluorescence intensity was measured using 
Slidebook.  A Laplacian 2-D spatial filter was applied to the MIP to highlight 
mitochondrial structures and an intensity threshold was applied to the images to mask 
mitochondrial objects. A shape factor consisting of p2/4?A (p=perimeter and A=area) 
was applied to all the mitochondrial objects in each cell type (Koopman et al., 2005). 
 
 
Mitochondrial DNA Isolation and Quantification 
 
Total cellular DNA was extracted using the DNeasy kit (Qiagen). The amount of 
mtDNA present per nuclear genome was determined by quantitative real-time PCR using 
the following primer pairs: mtDNA forward primer, cctatcacccttgccatcat; mtDNA reverse 
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primer, gaggctgttgcttgtgtgac. To quantify nuclear DNA we used primers for the Pecam 
gene on chromosome 6 Nuclear DNA forward primer, atggaaagcctgccatcatg;  
Nuclear DNA reverse primer, tccttgttgttcagcatcac. Quantification of relative copy number 
differences was carried out by analyzing the difference in threshold amplification 
between mtDNA and nuclear DNA (delta delta C(t) method). 
 
 
Mitochondrial Membrane Potential and Image Analysis 
 
Cells were stained in dark with 10 nM tetramethylrhodamine (TMRM) 
(Invitrogen) in Hank’s balanced salt solution (HBSS, Gibco) at 37°C for 20 minutes. 
Images were captured on a Marianas spinning disk confocal (SDC) imaging system using 
a 63X 1.4 NA Apochromat objective (Zeiss). Imaging conditions (laser excitation power 
at 561 nm, exposure time and camera gain) were identical for all samples. Mean pixel 
intensity values of all mitochondria in the image (representative of mitochondrial 
potential) were obtained by masking the signal with Ridler-Calvard automatic 
thresholding algorithm implemented in Slidebook 5.0 (3i). 
 
 
Transmission Electron Microscopy 
 
Wild-type and Mcl-1-deficient MEFs and Mcl-1-deleted livers were fixed in 2.5% 
gluteraldehyde in 0.1M sodium cacodylate buffer and post fixed in 2% osmium tetroxide 
in 0.1M sodium cacodylate buffer with 0.3% potassium ferrocyanide for 2 hours.  Tissue 
was enblocked stained with 4% aqueous uranyl acetate for 1 hour then dehydrated 
through a series of graded ethanol to propylene oxide, infiltrated and embedded in epoxy 
resin and polymerized at 70?C overnight.  Semi-thin sections (0.5 ?m) were stained with 
toluidine blue for light microscope examination. Ultra-thin sections (80 nm) were cut and 
imaged using a JEOL 1200 electron microscope with an AMT XR 111 camera. 
 
 
Immuno-electron Microscopy 
 
Mitochondria were isolated from pI-pC-treated wt or Mcl-1f/f plus Mx1-Cre liver.  
Mitochondrial fractions were fixed for 2 hours using a 4% Paraformaldehyde in 0.1M 
Phosphate Buffer.  The fractions were then embedding in a 12% gelatin and then 
immersed in 2.3M sucrose overnight. They were frozen using liquid nitrogen and were 
then cryo-sectioned at a thickness of 85 nm and a temperature of  -110°C using a Leica 
UCT ultramicrotome.  The cryo-sections were placed on formvar coated nickel grids and 
labeled with anti-MCL-1 primary antibody (Abcam) and protein A gold secondary (Cell 
Microscopy Center) as described previously (Peters et al., 2006).  Briefly, Data 
Acquisition was carried out utilizing a JEOL 1200 EX II electron microscope equipped 
with an 11 megapixel AMT camera. 
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Immunofluorescence 
 
Mcl-1-deficient MEFs were grown in 4-well chamber slides and transfected using 
Fugene6 with Mcl-1 constructs.  Cells were treated with Mitotracker red (Invitrogen) for 
45 minutes at 37?C.  Cells were fixed in 4% paraformaldehyde and immunostained with 
anti-MCL-1 (Rockland) and Alexa488 anti-rabbit IgG (Invitrogen).  Images were 
collected using Leica DM IRBE microscope equipped with a Leica TCS Confocal 
System using a 63X magnification. 
 
 
Enzymatic Activity of Electron Transport Chain Components 
 
For all the enzymatic assays mitochondria were isolated from pI-pC-treated wt or 
Mcl-1f/f plus Mx1-Cre liver (Opferman et al., 2005).  The activity of NADH-ubiquinone 
oxidoreductase (complex I) was assayed as previously described (Frost et al., 2005). 
Briefly, mitochondria were lysed with dodecyl maltoside in a phosphate buffer (pH 7.4) 
containing MgCl2 and NADH.  The reaction was started by the addition of CoQ1, upon 
which NADH oxidation was followed at 340 nm for several minutes.   Changes in 
absorbance prior to the addition CoQ1 were recorded as a blank.  Activity was calculated 
using the extinction coefficient 6.22 mM-1cm-1 for NADH.  Succinate-ubiquinone 
oxidoreductase (complex II) activity was assayed by measuring the succinate dependent 
reduction in DCIP, mediated by CoQ1.  The reaction was followed by recording 
absorbance at 600 nm following the addition of succinate (Miyadera et al., 2003).  
Succinate-independent absorbance changes were measured as a blank.  Activity was 
calculated using the extinction coefficient of 21 mM-1cm-1 for DCIP.  Cytochrome c 
oxidase activity (complex IV) was assayed by measuring the oxidation of cytochrome c 
at 550 nm and calculated using the extinction coefficient of 19.6 mM-1cm-1as previously 
described (Miro et al., 1998).  Pyruvate dehydrogenase (PDH) activity was assayed by 
measuring the pyruvate-dependent reduction of INT, mediated by PMS, as previously 
described (Hinman and Blass, 1981). Briefly, mitochondria lysed with dodecyl maltoside 
were incubated in a Tris (pH 7.4) buffer containing NAD+, TPP, CoA, MgCl2, BSA, 
PMS, and pyruvate.   Absorbance changes at 500 nm were recorded and activity was 
calculated using the absorption coefficient 12.4 mM-1cm-1.  Identical samples lacking 
either mitochondria or pyruvate were prepared as blanks. 
 
 
Isolation of Respiratory Complexes and Supercomplexes 
 
Mitochondria were isolated from pI-pC-treated wt or Mcl-1f/f plus Mx1-Cre liver.  
Mitochondrial isolation was carried out as described previously (Fernandez-Vizarra et al., 
2002).  Isolation of the complexes and supercomplexes was completed as previously 
described (Acin-Perez et al., 2008). 
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Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) 
 
Mitochondrial membrane proteins (20 ?g) were loaded and run on 3-12% first-
dimension (1D) gradient BN-PAGE gel was as described earlier (Acin-Perez et al., 
2008).  The 1D gel was transferred onto PVDF and immunoblotted with indicated 
antibodies. 
 
 
?-Phosphatase Treatment 
 
Wild-type MEFs were treated with DMSO or 10μM MG-132 for 4 hours after 
which the cells were lysed in 10mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA, 1% 
NP-40, 1mM DTT, 1mM PMSF containing protease inhibitors on ice for 30 minutes.  
Lysates were incubated with or without ?-protein phosphatase (New England Biolabs) for 
??? ??????????????????????????????????????????????????????????????????-MCL-1 
(Rockland), anti-Phospho-AKT(Ser473) (Cell Signaling), anti-AKT (Cell Signaling) and 
anti-Actin (Millipore). 
 
 
Edman Sequencing of MCL-1 
 
MCL-1 protein was immunoprecipitated from transiently-transfected 293T cells 
using FLAG Lysis Buffer (30 mg of input), resolved by SDS-PAGE, and transferred to 
PVDF membrane.  Coomassie-stained membrane was excised and submitted to the W.M. 
Keck Foundation Biotechnology Resource Laboratory at Yale University and subjected 
to 8 rounds of N-terminal sequencing. 
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CHAPTER 3.    RESULTS* 
 
 
Mcl-1-deletion Results in Mitochondrial Morphology Defects 
 
 SV40-transformed wild-type (wt) or Mcl-1f/f Rosa-ERCreT2 murine embryonic 
fibroblasts (MEFs) in which endogenous Mcl-1 can be deleted by tamoxifen-mediated 
induction of the Cre-recombinase were generated (hereafter referred to as Mcl-1-deletion) 
(Fig. 3.1a).  Inducible Mcl-1-deletion in MEFs did not trigger spontaneous apoptosis 
(Fig. 3.1b), but resulted in defective proliferation (Fig. 3.1c).  Notably, Mcl-1-deletion 
induced the appearance of punctate mitochondria and the loss of the normal tubular 
mitochondrial network that was present in control cells (Fig. 3.2a, b).  Furthermore, 
ultrastructural defects including defective cristae harboring balloon-like, vesicular 
structures were readily apparent within the majority of mitochondria in Mcl-1-deficient 
MEFs (Fig. 3.2c, d).  These abnormal cristae morphologies were not limited to 
transformed MEFs as similar defects were observed in primary Mcl-1-deleted liver 
mitochondria (Fig. 3.3a).  Proteins involved in oxidative phosphorylation are enriched in 
the inner mitochondrial membranes (IMM) that make up the cristae (Gilkerson et al., 
2003; Vogel et al., 2006); therefore, we assessed whether Mcl-1-deletion altered the 
enzymatic activity of the respiratory chain complexes.  Mcl-1-deletion in mouse liver 
mitochondria significantly decreased the ability of NADH dehydrogenase (complex I), 
succinate dehydrogenase (complex II), and cytochrome c oxidase (complex IV) to 
transfer electrons; whereas pyruvate dehydrogenase (PDH) activity was unchanged (Fig. 
3.3b).  Deletion of Mcl-1 in transformed MEFs did not result in massive apoptosis, 
probably because MEFs do not express high levels of BH3 proteins; thus, are not 
“primed” for death.  However, the small amount of apoptosis observed may be enough to 
cause a change in proliferation since cell growth is logarithmic and cell death is not. Loss 
of MCL-1 expression in MEFs and hepatocytes did result in dysregulation of the normal 
reticular mitochondrial network, cristae morphological abnormalities, and defects in 
electron transport chain enzymatic function. 
 
 
MCL-1 Localizes to Two Distinct Mitochondrial Sub-compartments 
 
To understand the mechanisms underlying the dependence on MCL-1 for normal 
cristae morphology, we investigated the localization of MCL-1 within mitochondria.  By 
immunoblot analysis MCL-1 appeared as a doublet or triplet in percoll-purified liver 
mitochondria devoid of contaminating endoplasmic reticulum (ER) (Fig. 3.4a).  MCL-1 
is a phosphorylated protein (Domina et al., 2004; Maurer et al., 2006; Morel et al., 2009); 
however, phosphatase-treatment of cell lysates did not abolish the 40 kD species  
 
 
* Reprinted with permission. Perciavalle, R.M., Stewart, D.P., Koss, B., Lynch, J., 
Milasta, S., Bathina, M., Temirov, J., Cleland, M.M., Pelletier, S., Schuetz, J.D., et al. 
(2012). Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples 
mitochondrial fusion to respiration. Nature Cell Biology 14, 575-583. 
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Figure 3.1. Inducible Mcl-1-deletion in MEFs Does Not Affect the Cell Viability. 
(a) Mcl-1f/f Rosa-ERCreT2 or wild-type (wt) Rosa-ERCreT2 MEFs (control MEFs) were 
treated with tamoxifen or DMSO for indicated times to induce deletion of endogenous 
Mcl-1 then immunoblotted for MCL-1 or Actin (loading control).  (b) Mcl-1f/f Rosa-
ERCreT2 or wt control MEFs were treated with tamoxifen or DMSO (vehicle control) for 
indicated times, to induce deletion of endogenous Mcl-1, and assessed for cell death. 
Annexin-V and PI double-negative cells were scored as viable. Bars represent the 
average of 3 independent experiments and the error bars denote the SEM. (c) Mcl-1f/f 
Rosa-ERCreT2 or wt Rosa-ERCreT2 MEFS were treated with tamoxifen (48 hours), 
seeded, and counted by hemocytometer at the indicated times.  The data represent 
averages and SEM of 3 independent experiments. 
  
MCL-1
Actin
Time (hrs)
Tamoxifen
48
-
wt 
Rosa-
ERCreT2
Mcl-1f/f
Roas-
ERCreT2
-
0
+
48
-
96
+
96
-
0
-
48
-
96
+
48
+
96
a b
c
0 1 2 3 4 5
0
1
2
3
4
5
6
7
To
ta
l C
el
l N
um
be
r (
x1
06
)
 
 
wt Rosa-ERCreT2
Mcl-1f/f Rosa-ERCreT2
0 20 40 60 80 100
0
20
40
60
80
100
Pe
rc
en
t V
ia
bl
e 
Ce
lls
 (A
nn
ex
in
V
-  P
I- )
Time (hrs)
 wt MEF + DMSO
 wt MEF + Tamoxifen
 Mcl-1f/f Rosa-ERCreT2 
+ DMSO
 Mcl-1f/f Rosa-ERCreT2
 + Tamoxifen
Time (days)
 26 
Figure 3.2. Inducible Mcl-1-deletion in MEFS Results in Mitochondrial 
Morphology Defects. 
(a) Mcl-1f/f Rosa-ERCreT2 or wt Rosa-ERCreT2 MEFs expressing matrix-targeted 
DsRed fluorescent protein were treated with DMSO or tamoxifen for 96 hours to induce 
deletion of endogenous Mcl-1, then imaged to detect mitochondrial morphology. Scale 
bars represent 10?m. (b) Average shape factor of mitochondrial matrix for Mcl-1f/f Rosa-
ERCreT2 or control MEFs 96 hours after deletion.  A shape factor of 1.0 indicates 
circular mitochondria and the higher the number, the more reticular the network.  A shape 
factor consisting of p2/4?A (p=perimeter and A=area) was applied to all the 
mitochondrial objects in each cell type (Koopman et al., 2005).  Error bars represent the 
standard error of the mean (SEM) from 10 imaged cells (~3000 mitochondria) and 
statistical significance was determined by unpaired t-test (*p<0.01).  (c) Transmission 
electron micrographs of wt or Mcl-1-deficient MEFs.  Scale bars represent 500 nm.  (d) 
Quantification of mitochondrial cristae morphology from wt or Mcl-1-deficient MEFs.  
Mitochondria were counted from ~100 individual cells and scored for normal (lamellar) 
or ballooned and swollen cristae (disorganized).  Error bars indicated the SEM from 3 
independent experiments. 
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Figure 3.3. Mcl-1-deletion Induces Mitochondrial Abnormalities. 
(a) Transmission electron micrographs of pI-pC-treated Mcl-1f/f Mx1-Cre mouse liver 14 
days after pI-pC treatment.  Size bars represent 500 nm. (b) Enzymatic assays for 
indicated electron transport chain components and pyruvate dehydrogenase (PDH) from 
mouse liver mitochondria prepared from Mcl-1f/f Mx1-Cre or wt Mx1-Cre (wt) mice 14 
days after treatment with pI-pC.  Three independent animals were assayed in triplicate 
(n=9) and error bars indicated the SEM.  Statistical significance was determined by 
unpaired t-test (*p<0.01). 
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Figure 3.4. Origin of MCL-1 Protein Species. 
(a) Crude or Percoll-purified mouse liver mitochondria were western blotted for 
expression of MCL-1, Protein Disulphide Isomerase (PDI, endoplasmic reticulum, ER), 
or cytochrome c (inner membrane space, IMS).  (b) Wild-type (wt) MEFs were either 
treated with or without proteasome inhibitor (MG-132), then cell lysates were incubated 
in the absence or presence of ?-protein phosphatase.  Lysates were immunoblotted with 
anti-MCL-1, anti-Phospho-AKT (Ser473), anti-AKT, and Actin for loading control.  (c) 
Lysates from wt MEFs or Mcl-1-deleted stably-expressing vector, wild-type Mcl-1, or 
Mcl-1 in which its ATG start codon was mutated to TAG (Mcl-1?ATG) were 
immunoblotted using anti-MCL-1 and anti-Actin for loading control. (d) Lysates from 
Mcl-1-deleted or wt MEFs stably-expressing vector, wild-type Mcl-1, or Mcl-1 in which 
the putative cryptic splice donor/acceptor pair (nucleotide: 52 G to A and 189 G to T) 
was mutated (Mcl-1SD;SAmut) were immunoblotted using anti-MCL-1 and anti-Actin 
(loading control).  
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indicating its slower migration is not due to differential phosphorylation (Fig. 3.4b).  It 
has been proposed that non-canonical translational initiation at a non-ATG leads to the 
production a faster-migrating 36 kD truncated protein (Warr and Shore, 2008); however, 
removal of MCL-1's start codon did not produce a 36 kD protein, instead it produced a 31 
kD truncated-protein from a downstream ATG codon (Fig. 3.4c).  It has also been 
proposed that non-canonical mRNA splicing generates the 36 kD species (Kojima et al., 
2010); however, ablation of the putative splice donor and acceptor pairs still produced the 
doublet in cells (Fig. 3.4d).  Thus, proteolytic cleavage appears to be the most likely 
contributor to generate the faster migrating 36 kD species (De Biasio et al., 2007; Huang 
and Yang-Yen, 2010).  Indeed, amino-terminal Edman sequencing of 
immunoprecipitated MCL-1 detected two amino-terminal cleavage sites: the first 
between MCL-1's isoleucine-10 and glycine-11 and another between leucine-33 and 
valine-34.  Consequently, proteolysis of MCL-1's amino-terminus gives rise to three 
different molecular weight MCL-1 species: full-length (40 kD), cleaved at isoleucine-10 
(38 kD), and cleaved at leucine-33 (36 kD).   
 
Unexpectedly, the variant forms of MCL-1 exhibited different mitochondrial sub-
localization; the slowly migrating bands of MCL-1 (40 kD and 38 kD) were enriched in 
the OMM, while the faster migrating form (36 kD) was only detected in the mitoplast 
fraction, consisting mainly of IMM and matrix (Fig. 3.5a).  Indeed, while both the 40 kD 
and 36 kD forms of MCL-1 were tightly associated with disrupted and alkali-washed 
mitochondrial membranes, only the 38 kD species exhibited a looser association with 
membranes (Fig. 3.5b).  Furthermore, when mitochondria isolated from MEFs were 
treated with proteinase K, the 40 kD and 38 kD forms of MCL-1 were sensitive to 
protease digestion, but the 36 kD species remained resistant to degradation even after 
osmotic shock-mediated permeabilization of the OMM (Fig. 3.5c).  Moreover, 
mitochondria from mouse liver and human non-small cell lung cancer cell lines exhibited 
the same protease sensitivity, suggesting that the sub-mitochondrial localization of MCL-
1 is conserved in both primary murine tissues and human cell lines (Fig. 3.5d, e).  
Immunoelectron microscopy of isolated liver mitochondria also indicated that 
endogenous MCL-1 localized to both the OMM and IMM (Fig. 3.6).  Together, these 
results indicate that the 40 kD and 38 kD forms of MCL-1 reside on the outer leaflet of 
the OMM, whereas the 36 kD form is associated with the inner membrane and is 
confined within the mitochondrial matrix. 
 
During mitochondrial protein import, nuclear encoded proteins are processed by 
importation machinery consisting of the translocases of outer membrane (TOM) and 
inner membrane (TIM) proteins (Schmidt et al., 2010).  RNAi-mediated gene silencing of 
either TOM40 or TIM50 prevented MCL-1's mitochondrial import rendering it 
completely protease sensitive (Fig. 3.7).  Accordingly, MCL-1 undergoes TOM- and 
TIM-dependent mitochondrial import. 
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Figure 3.5. MCL-1 Resides in Different Sub-mitochondrial Localizations. 
(a) Mouse liver mitochondria (HM) were sub-fractionated into outer mitochondrial 
membrane or mitoplast and western blotted for MCL-1, BCL-XL (outer mitochondrial 
membrane, OMM), Prohibitin1 (inner mitochondrial membrane, IMM), or MnSOD 
(matrix). (b) Mouse liver mitochondria (HM) were swollen and sonicated to disrupt 
membranes, washed with alkali buffer (pH 11.5) to detach loosely-associated proteins 
from membranes, and then re-isolated by ultra-centrifugation.  Supernatant (Supe) and 
membrane fractions (Pellet) were western blotted for MCL-1, Prohibitin1, or MnSOD.  
(c, d, & e) Mitochondria isolated from (c) wt MEFs, (d) wt mouse liver, or (e) human 
Non-Cell Lung Cancer (NSCLC) cells were subjected to proteinase K (PK) proteolysis to 
digest exposed proteins, osmotic shock (OS) was used to disrupt the outer mitochondrial 
membrane, and detergent (SDS) was used to disrupt both inner and outer mitochondrial 
membranes.  Lysates were resolved and subjected to immunoblot analyses. 
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Figure 3.6. MCL-1 Is Localized to Both the Outer and Inner Mitochondrial 
Membranes. 
Mouse liver mitochondria from Mcl-1f/f Mx1-Cre (Mcl-1-deleted) or wt Mx1-Cre (wt) 
mice 14 days after treatment with pI-pC were fixed 4% paraformaldehyde in 0.1 M 
Phosphate Buffer and subjected to immuno-electron microscopy.  Magnification is 
20,000X and scale bar represents 100 nm. 
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Figure 3.7. MCL-1 Undergoes TIM/TOM Mitochondrial Import. 
Mitochondria isolated from wt MEFs transfected with control or siRNA-oligos specific to 
TOM40 or TIM50 were subjected to protease treatment as described in Fig. 3.5. 
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MCL-1 Possesses a Mitochondrial Targeting Sequence 
 
MCL-1 shares sequence homology to BCL-2 in its carboxy-terminal region; 
however, its amino-terminus is poorly conserved (Kozopas et al., 1993).  To define the 
domains necessary for appropriate localization to mitochondria, MCL-1 mutants were 
generated (Fig. 3.8a). Both MCL-1's amino- and carboxy-terminal domains were 
necessary for its proper mitochondrial localization and generation of a doublet by 
immunoblot analysis (Fig. 3.8b, c). Proteins imported into the mitochondrial matrix often  
contain mitochondrial targeting sequences (MTS) (Schmidt et al., 2010). To determine if 
the amino-terminus on MCL-1 contains a MTS, the first 50 amino-terminal amino acids 
of MCL-1 were fused to the amino-terminus of human BCL-2 (hBCL-2).  Human BCL-2 
is normally restricted to the OMM; however, the chimeric protein formed a doublet of 
which the faster migrating species appeared in the matrix, thus validating that MCL-1's 
amino-terminus possesses an MTS (Fig. 3.8d).  Imported mitochondrial proteins often 
possess MTS's containing charged residues (Schmidt et al., 2010).  Mutagenesis of the 
arginine residues at MCL-1's positions 5 and 6 to alanine (hereafter called MCL-1OM) 
maintained its localization to mitochondria, but abrogated the formation of MCL-1's 36 
kD form (Fig. 3.9a, b, c).  Notably, MCL-1OM was completely sensitive to proteolysis 
indicating that the mutagenesis blocks mitochondrial import (Fig. 3.9d).  To generate a 
MCL-1 mutant that resides solely within the mitochondrial matrix, we used the 
mitochondrial targeting sequence of matrix-localized ATP-synthase (Pfanner et al., 1987) 
and fused it to amino-truncated MCL-1 (hereafter called MCL-1Matrix) (Fig. 3.9a).  MCL-
1Matrix localized to mitochondria, and only produced a single protein species (Fig. 3.9b, 
c).  Moreover, MCL-1Matrix was completely resistant to protease attack even under 
conditions of osmotic shock illustrating that it localizes to the matrix (Fig. 3.9d). 
 
 
Inhibition of Cell Death Requires Outer Membrane-localized MCL-1 
 
Given that MCL-1 antagonizes cell death, we assessed the anti-apoptotic activities 
of the different mitochondrial localized mutants of MCL-1.  Similar levels of wt MCL-1, 
MCL-1OM, or MCL-1Matrix were stably expressed in Mcl-1f/f Rosa-ERCreT2 MEFs (Fig. 
3.10a).  Mcl-1-deletion in MEFs did not induce spontaneous apoptosis (Fig. 3.1 b), but 
rendered them highly susceptible to cell death stimuli (Fig. 3.10b, c).  Expression of 
either wt MCL-1 or MCL-1OM protected the MEFs from apoptosis; however, MCL-1Matrix 
expressing MEFs were completely sensitive to cell death (Fig. 3.10b, c).  Furthermore, 
the expression of hBCL-2 in the Mcl-1-deleted MEFs rendered cells substantially more 
resistant to death stimuli (Fig. 3.10b, c).  MCL-1 binds and sequesters pro-apoptotic 
BH3-only molecules, such as BIM, preventing OMM permeabilization and activation of 
the downstream apoptotic cascade (Opferman et al., 2003).  Both the 40 kD species of wt 
MCL-1 and MCL-1OM co-immunoprecipitated with pro-apoptotic BIM; however, no 
interaction was detectable between BIM and the 36 kD species of wt MCL-1 or between 
BIM and MCL-1Matrix (Fig. 3.10d).  Thus, MCL-1OM can bind pro-apoptotic modulators 
and prevent cell death similarly to wt MCL-1, but MCL-1Matrix cannot sequester pro-
apoptotic modulators or prevent apoptosis. 
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Figure 3.8. Both the Amino (N)- and Carboxy (C)-termini Are Required for 
Proper Mitochondrial Localization of MCL-1. 
(a) Schematic illustration of MCL-1 deletion mutants. Yellow boxes indicate BCL-2 
homology (BH) domains and the red box indicates the C-terminal hydrophobic domain. 
(b) Confocal immunofluorescence of Mcl-1-deficient MEFs transiently-expressing 
indicated Mcl-1 constructs were fixed and stained for MCL-1 (green), mitochondria 
(Mitotracker, in red), and nucleus (DAPI, in blue). Co-localization of green and red 
channels is shown in yellow overlay. Size bars represent 10?m.  (c) Whole cell lysates 
(WCL), isolated heavy membranes (HM) enriched for mitochondria or cytosolic (cyto) 
sub-cellular fractions were isolated from Mcl-1-deleted MEFs stably-expressing indicated 
MCL-1 constructs.  Fractions were western blotted for MCL-1, BAX (cytosolic marker) 
or MnSOD (mitochondrial marker). (d) Mitochondria from Mcl-1-deficient MEFs stably-
expressing human BCL-2 (hBCL-2) or a chimeric fusion of the first 50 amino acids of 
MCL-1 to hBCL-2 (mMCL-150-hBCL-2) were subjected to protease treatment as 
described in Fig. 3.5.  Both the fusion protein and hBCL-2 were detected with anti-
hBCL-2 antibody. 
 
 36 
 
  
a
W
C
L
C
yt
o
H
M
W
C
L
C
yt
o
H
M
W
C
L
C
yt
o
H
M
Mcl-1 Mcl-1ΔN 
MCL-1
BAX (Cytosol)
MnSOD
Mcl-1ΔC
ΔN
67
331
ΔC
wt CBH1 BH2BH3BH4 MCL-1
CBH1 BH2BH3MCL-1ΔN
BH1 BH2BH3BH4 MCL-1ΔC
b
c
MCL-1 Mitotracker DAPI Overlay
Mcl-1ΔC 
Mcl-1ΔN 
Mcl-1
d
PK
SDS
OS
hBCL-2
mMCL-150-
hBCL-2
Opa1
MnSOD
+- + +-
-- +- -
-- + + -
+- +-
-- - -
-- + +
mBCL-2
hBCL-2
+
+
-
 37 
Figure 3.9. MCL-1 Mutants Restrict Mitochondrial Localization. 
(a) Schematic illustration of MCL-1 mutants. Yellow boxes indicate BCL-2 homology 
(BH) domains and the red box indicates the carboxy (C)-terminal hydrophobic domain. 
Point mutations are indicated with the original amino acid, site-position and mutated 
residue.  N. crassa ATP-synthase MTS is indicated in green. (b) Confocal 
immunofluorescence of Mcl-1-deficient MEFs transiently expressing indicated Mcl-1 
constructs were fixed and stained for MCL-1 (green), mitochondria (Mitotracker, in red), 
and nucleus (DAPI, in blue). Co-localization of green and red channels is shown in 
yellow overlay. Scale bars represent 10?m.  (c) Mitochondria enriched, heavy membrane 
(HM) or cytosol (cyto) sub-cellular fractions were isolated from Mcl-1-deficient MEFs 
stably-expressing indicated constructs. Whole cell lysates (WCL) were run as a control.  
Fractions were resolved and western blotted for MCL-1, BAX (cytosol) or MnSOD 
(matrix). (d) Mitochondria from Mcl-1-deficient MEFs stably-expressing indicated 
constructs were subjected to protease treatment as described in Fig. 3.5. 
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Figure 3.10. Anti-apoptotic Activity of MCL-1 Requires Localization to the Outer 
Mitochondrial Membrane. 
(a) Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs were treated for 
48 hours with tamoxifen to induce deletion of endogenous Mcl-1 then western blotted for 
MCL-1, hBCL-2, or Actin (loading control). Vector-expressing, tamoxifen-treated wt 
Rosa-ERCreT2 MEFs (lane 1) serve as control. (b & c) Rosa-ERCreT2 MEFs stably-
expressing indicated constructs were treated for 96 hours with tamoxifen to induce 
deletion of endogenous Mcl-1 and were administered indicated doses of (b) staurosporine 
for 16 hours or (c) etoposide for 24 hours after which cell death was determined.  
Annexin-V and PI double-negative cells were scored as viable. Bars represent the 
average of 3 independent experiments and the error bars denote the SEM.  Vector-
expressing, tamoxifen-treated wt Rosa-ERCreT2 MEFs serve as control.  (d) Lysates 
were immunoprecipitated with anti-BIM or anti-rat IgG antibody and immune complexes 
were resolved and immunoblotted for MCL-1 and hBCL-2.  Endogenous murine BCL-2 
(mBCL-2) serves as a control for equal BIM immunoprecipitation.  1/10th input of 
immunoprecipitation is depicted.  Post-immunoprecipitated supernatants (Unbound Flow 
Through) indicate non-precipitated proteins remaining in lysate. 
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MCL-1 Matrix-localized MCL-1 Is Required for Normal IMM Structure and 
Efficient Mitochondrial Fusion 
 
Since Mcl-1-deletion resulted in ultrastructural abnormalities in both primary and 
transformed cells (Fig. 3.2c, d & Fig. 3.3a) we investigated whether reintroduction of 
MCL-1Matrix can rescue the abnormal IMM structure.  Expression of either wt MCL-1 or 
MCL-1Matrix largely restored normal IMM structure whereas MCL-1OM did not (Fig. 
3.11a, b). Because mitochondrial structure is regulated by the opposing processes of 
fission and fusion (Chen et al., 2010) and Mcl-1-deleted cells had fragmented 
mitochondria (Fig. 3.2a, b), we asked which form of MCL-1 is required for normal 
matrix fusion.  Accordingly, we used photo-activatable-GFP targeted to the 
mitochondrial matrix (Karbowski et al., 2004).  Upon Mcl-1-deletion, there was a 
significant delay in mitochondrial fusion that could be corrected by expression of either 
wt MCL-1 or MCL-1Matrix but not by MCL-1OM or hBCL-2 (Fig. 3.11c, d).  Furthermore, 
expression of human MCL-1 could ameliorate the delay in fusion and functionally 
compensated for loss of mouse MCL-1 implying this function is evolutionarily conserved 
(Fig. 3.12).  Therefore, matrix-localized MCL-1 is necessary to promote normal IMM 
structure, efficient mitochondrial fusion and maintenance of the mitochondrial reticular 
network. 
 
 
Normal Mitochondrial Bioenergetics Requires Matrix-localized MCL-1 
 
Whereas the structure of the IMM is intricately linked to the metabolic status of the 
mitochondria (Vogel et al., 2006) and defects in mitochondrial morphology are 
associated with respiratory dysfunction (Chen et al., 2010), we examined the role of 
MCL-1Matrix in promoting efficient ATP generation and oxidative phosphorylation.  
Transformed MEFs generate energy predominantly by glycolysis rather than by oxidative 
phosphorylation, therefore to stimulate mitochondrial respiration they were cultured in 
glucose-free media supplemented with galactose (Reitzer et al., 1979; Rossignol et al., 
2004).  Under these conditions, Mcl-1-deletion significantly reduced ATP levels, but 
expression of either wt MCL-1 or MCL-1Matrix restored normal ATP levels (Fig. 3.13a).  
In contrast, expression of either MCL-1OM or hBCL-2 in the Mcl-1-deleted MEFs did not 
rescue ATP levels, suggesting that merely restoring anti-apoptotic function is insufficient 
to promote normal energy production (Fig. 3.13a).  Since the proton gradient across the 
IMM drives ATP synthesis, we assessed whether the mitochondrial membrane potential 
was altered in cells lacking MCL-1.  Indeed, Mcl-1-deletion decreased mitochondrial 
membrane potential, which was improved by stable expression of either wt MCL-1 or 
MCL-1Matrix, but not MCL-1OM (Fig. 3.13b, c).  When grown in galactose-media, Mcl-1-
deleted MEFs also exhibited slower proliferation compared to control cells (Fig. 3.13d).  
Expression of either wt MCL-1 or MCL-1Matrix corrected the proliferative defect, whereas 
MCL-1OM or hBCL-2 expression was unable to compensate for endogenous Mcl-1-
deletion (Fig. 3.13d).  This suggests that the proliferative defect is not due to a small 
amount of apoptosis since MCL-1Matrix does not reatain anti-apoptotic activity but 
proliferates faster than MCL-1OM.  Consequently, MEFs lacking matrix-localized MCL-1  
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Figure 3.11. Lacking Matrix-localized MCL-1 Results in Mitochondrial IMM 
Structure and Fusion Defects. 
(a) Transmission electron micrographs (12,000X) of Mcl-1f/f Rosa-ERCreT2 MEFs 
stably-expressing indicated constructs were treated with tamoxifen to induce deletion of 
endogenous Mcl-l.  Scale bars represent 500 nm.  (b) Quantification of mitochondrial 
cristae morphology from Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated 
constructs that were treated with tamoxifen to induce deletion of endogenous Mcl-1.  
Mitochondria were cunted from ~100 individual cells and scored for normal (lamellar) or 
ballooned and swollen cristae (disorganized).  Error bars indicated the SEM from 3 
independent experiments. (c) Mitochondrial fusion was measured 96 hours after Mcl-1-
deletion in Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs. Cells 
were transiently-transfected with photoactivatable-GFP (PA-GFP) targeted to the 
mitochondrial matrix.  Depicted are representative images from 2, 30, and 60 minutes 
after PA-GFP activation. Scale bars represent 10?m. (d) Quantitation of the rate of 
mitochondrial fusion measured 96 hours after Mcl-1-deletion as the ratio of remaining 
activated mitochondrial area.  Data represent average and SEM of fluorescence area over 
time of 3 independent experiments (n=16 cells).  As mitochondria fuse, the PA-GFP 
signal dilutes decreasing intensity of signal in the area of activation. 
 43 
 
  
a
b
Mcl-1Matrix
Mcl-1OM
Mcl-1
Vector
2 30 60
Time After Photoactivation (min)c
0 20 40 60 80 100
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Re
m
ai
ni
ng
 R
at
io
 o
f A
ct
iva
te
d 
M
ito
ch
on
dr
ia
Time (Minutes)
 
 
 
 
Vector
Mcl-1
Mcl-1OM
Mcl-1Matrix
hBCL-2
_____
_____
Mcl-1OM
Mcl-1Matrix
Mcl-1
_
_
_____
0
25
50
75
100
Cr
ist
ae
 M
or
ph
ol
og
y 
(%
 o
f m
ito
ch
on
dr
ia
)
 Lamellar
 Disorganized
Mcl-1OM Mcl-1MatrixMcl-1Vector
d
 44 
 
 
Figure 3.12. Human MCL-1 Rescues Mitochondrial Fusion Defect. 
Mitochondrial fusion was measured 96 hours after Mcl-1-deletion in Mcl-1f/f Rosa-
ERCreT2 MEFs stably-expressing indicated constructs. Cells were transiently-transfected 
with photoactivatable-GFP (PA-GFP) targeted to the mitochondrial matrix.  
Quantification rate of mitochondrial fusion is indicated as a ratio of remaining activated 
mitochondrial area.  Data represent average and SEM of fluorescence area over time of 3 
independent experiments (n=16 cells). 
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Figure 3.13. Matrix-localized MCL-1 Is Required for Efficient Bioenergetics and 
Proliferation. 
(a) Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs were grown in 
glucose-free media containing galactose and treated for 96 hours with tamoxifen to 
induce deletion of endogenous Mcl-1 and total cellular ATP was evaluated in galactose 
media.  Vector-expressing, tamoxifen-treated wt Rosa-ERCreT2 MEFs serve as positive 
control.  Data represent the averages of 3 independent experiments and the error bars 
denote the SEM.  Statistical significance was determined by unpaired t-test (*p<0.01).  
(b) Quantification of mitochondrial membrane potential from Mcl-1f/f Rosa-ERCreT2 
MEFs, stably-expressing indicated constructs, were treated for 96 hours with tamoxifen 
to induce deletion of endogenous Mcl-1 and stained with 10 nM TMRM and imaged.  
Data represent average mean fluorescence intensities and SEM from 20 cells.  (c) Mcl-1f/f 
Rosa-ERCreT2 MEFs stably-expressing indicated constructs that were treated for 96 
hours with tamoxifen to induce deletion of endogenous Mcl-1 and were stained with 20 
nM TMRM and imaged for mitochondrial membrane potential.   (d) Mcl-1f/f Rosa-
ERCreT2 MEFS stably-expressing indicated constructs were grown in glucose-free 
media containing galactose and were treated with tamoxifen (48 hours), seeded in 
glucose-free media containing galactose, and counted by hemocytometer at the indicated 
times. Vector-expressing, tamoxifen-treated wt Rosa-ERCreT2 MEFs serve as a control. 
The data represent averages and SEM of 3 independent experiments. Statistical 
significance of control versus Mcl-1-deleted and MCL-1OM versus MCL-1Matrix were 
determined by unpaired t-test (p<0.001). 
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generate less energy, have decreased mitochondrial membrane potential, and grow poorly 
in galactose-media even in the presence of anti-apoptotic MCL-1 on the OMM.  
Respiratory complexes pass electrons through the electron transport chain 
components to reduce molecular oxygen, thus generating a proton gradient that drives 
ATP production by the F1F0-ATP synthase (Wallace, 1999).  Since both mitochondrial 
membrane potential and ATP production were decreased in Mcl-1-deleted MEFs (Fig. 
3.13a, b, c) we determined if respiration was altered by measuring oxygen consumption 
rates (OCR) using the Seahorse XF24 analyzer (Ferrick et al., 2008).  Mcl-1-deletion 
decreased basal OCR by ~50% compared to non-deleted MEFs (Fig. 3.14a).  Expression 
of either wt MCL-1 or MCL-1Matrix fully restored basal OCR; whereas neither MCL-1OM 
nor hBCL-2 expression could restore normal basal OCR (Fig. 3.14a).  To induce 
maximal OCR, a proton ionophore, FCCP, was added in order to dissipate the proton 
gradient, thereby activating maximum respiration (Nicholls, 1974).  Strikingly, Mcl-1-
deleted MEFs were incapable of increasing their OCR above basal rates when treated 
with FCCP (Fig. 3.14b); however, maximal OCR was completely restored by expression 
of either wt MCL-1 or MCL-1Matrix, but not by MCL-1OM or hBCL-2 (Fig. 3.14b).  
Collectively, matrix-localized MCL-1 is required for optimal oxidative phosphorylation 
in cells, a function that is acutely separate from its anti-apoptotic role at the OMM. 
Elevations in mitochondrial reactive oxygen species (ROS) are common in cells 
with mitochondrial dysfunction (Wallace, 1999). Upon Mcl-1-deletion, mitochondrial 
superoxide levels were elevated, but expression of either wt MCL-1 or MCL-1Matrix 
prevented the increase in mitochondrial superoxide production, consistent with their 
ability to rescue normal mitochondrial function (Fig. 3.14c).  In contrast, neither hBCL-2 
nor MCL-1OM could prevent increased superoxide generation, indicating that merely 
restoring anti-apoptotic function is inadequate to prevent superoxide induction (Fig. 
3.14c).  Hence, expression of the mitochondrial matrix form of MCL-1 is sufficient to 
both maintain mitochondrial respiration and prevent potentially dangerous ROS 
production in cells. 
 
 
MCL-1 Is Required for Assembly of F1F0-ATP Synthase Oligomers 
 
The movement of electrons through the respiratory complexes depends on the 
structure and assembly of the electron transport chain complexes (Acin-Perez et al., 
2008).  Structural and functional evidence has revealed that the individual electron 
transport chain complexes (I, II, III, and IV) organize into inter-complex assemblies 
known as supercomplexes, which are disrupted in the absence of one of their component 
complexes (Acin-Perez et al., 2008).  The supramolecular organization of respiratory 
complexes is hypothesized to increase the efficiency of electron transport and minimize 
ROS production (Acin-Perez et al., 2008; Genova et al., 2008).  Mcl-1-deletion did not 
affect the total protein expression of nuclear-encoded respiratory chain subunits; 
however, the mitochondrial DNA-encoded subunits of complex IV (Cox 1 and Cox 2) 
protein levels were decreased (Fig. 3.15a).  Therefore, we investigated whether the 
decreased Cox 1 and Cox 2 expression may be due to alterations in mitochondrial DNA  
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Figure 3.14. Cells Deficient in Matrix-localized MCL-1 Have Defects in Oxygen 
Consumption. 
(a & b) Oxygen consumption measured 96 hours after Mcl-1-deletion in Mcl-1f/f Rosa-
ERCreT2 MEFs stably-expressing indicated constructs under (a) basal and (b) FCCP-
uncoupled (maximal) respiration. Vector-expressing, tamoxifen-treated wt Rosa-
ERCreT2 MEFs serve as positive control. Experiments were performed in triplicate and 
the bars represent averages (n=9) and the error bars denote the standard of deviation. 
Statistical significance was determined by unpaired t-test (*p<0.01, **p<0.05). (c) 
Superoxide was detected by mitoSOX fluorescence 96 hours after Mcl-1-deletion in Mcl-
1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs. Vector-expressing, 
tamoxifen-treated wt MEFs serve as a negative control. Average mean fluorescence 
intensity (MFI) of 3 independent experiments and error bars indicate the SEM. Statistical 
significance was determined by unpaired t-test (*p<0.01). 
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Figure 3.15. MCL-1 Is Required for Assembly of Supercomplexes. 
(a) Total mouse liver lysates from Mcl-1f/f Mx1-Cre (Mcl-1-deleted) or wt Mx1-Cre (wt) 
mice 14 days after treatment with pI-pC were lysed in RIPA and resolved by SDS-PAGE.  
Immunoblot were probed to determine expression of Complex I (NDUFA9), Complex II 
(Fp70), Complex III (Core 2), Complex IV (Cox I and Cox 2), ATP Synthase subunit F0 
B (5F1), ATP Synthase F1 subunit beta (5B), Succinate dehydrogenase, MnSOD, and 
MCL-1.  Asterix (*) denotes mtDNA-encoded protein (b) Assessment of mtDNA and 
nDNA by quantitative real-time PCR. (c & d) Mouse liver mitochondria from Mcl-1f/f 
Mx1-Cre (Mcl-1-deleted) or wt Mx1-Cre (wt) mice 14 days after treatment with pI-pC 
were lysed in digitonin and resolved by blue native gel polyacrylamide electrophoresis 
(BN-PAGE) and blotted to determine native complexes and supercomplexes (SC). (c) 
complex I (CI, detected by NDUFA9), complex II (CII, detected by Fp70), complex III 
(CIII, detected by Core 2) and complex IV (CIV, detected by Cox I) and (d) ATP 
Synthase subunit F0 B (5F1), F1 subunit beta (5B). The native migration of monomers, 
dimers, and oligomers are denoted. 
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(mtDNA).  Indeed, Mcl-1-deletion decreased mtDNA content (Fig. 3.15b).  To 
investigate the structure of the respiratory complexes and supercomplexes, we used blue 
native-polyacrylamide gel electrophoresis (BN-PAGE).  Consistent with the loss of the 
Cox 1 and Cox 2 subunits of complex IV, Mcl-1-deleted liver mitochondria also 
exhibited aberrant assembly of large supercomplexes (composed of complexes I, III, and 
IV) as detected by Cox 1 immunoblot (Fig. 3.15c). This is in agreement with the effects 
of deletion of complex IV preventing the assembly of large supercomplexes (Acin-Perez 
et al., 2008; Diaz et al., 2006).  In contrast, the smaller respiratory supercomplexes 
appeared relatively unaffected by Mcl-1-deletion (Fig. 3.15c).  Therefore, Mcl-1-deletion 
results in diminished mtDNA, reduced protein expression of Cox 1 and Cox 2 subunits, 
and alterations in the large supercomplexes containing complexes I, III, and IV. 
 
The F1F0-ATP synthase also adopts supramolecular structures including the 
constitutive assembly of ATP synthase homo-dimers and higher-order homo-oligomers 
(Krause et al., 2005).  Furthermore, the assemblage into dimers and oligomers proffered 
as a determinant of the mitochondrial cristae structure and suggested to enhance 
efficiency of function (Giraud et al., 2002; Gomes et al., 2011; Thomas et al., 2008).  As 
such, mutations that prevent the oligomerization of ATP synthase result in disorganized 
cristae membranes that form concentric circles and onion-like structures (Bornhovd et al., 
2006; Paumard et al., 2002).  By BN-PAGE, Mcl-1-deficient liver mitochondria 
possessed less oligomeric ATP synthase and exhibited a corresponding increase in the 
monomer (Fig. 3.15d).  The lack of F1F0-ATP synthase oligomers was not due to loss of 
the individual subunits, implying that the defect is in the oligomerization of ATP 
synthase (Fig. 3.15a, d).  Accordingly, Mcl-1 is required for efficient assembly of F1F0-
ATP synthase oligomers and in the absence of Mcl-1 there is an increase in the 
monomeric form. 
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CHAPTER 4.    DISCUSSION 
 
 
MCL-1 in Normal Cells 
 
MCL-1 is a unique anti-apoptotic BCL-2 family member in that its genetic 
ablation results in cell autonomous deficiencies in a myriad of cellular lineages (Arbour 
et al., 2008; Dzhagalov et al., 2008; Dzhagalov et al., 2007; Opferman et al., 2005; 
Opferman et al., 2003; Rinkenberger et al., 2000; Steimer et al., 2009).  However, Mcl-1 
gene ablation disables both its anti-apoptotic activity at the OMM as well as its ability to 
facilitate mitochondrial function within the matrix.  For that reason, it will be important 
to determine the relative contributions of MCL-1's different functional roles for 
promoting the survival and development of hematopoietic and neuronal lineages.  It is 
conceivable that both roles of MCL-1 may be critical for normal cell viability.  For 
example, differentiating cells are subjected to expansion, selection, and homeostatic 
regulation often regulated by the access to growth factors in the cellular 
microenvironments.  As such, MCL-1's critical function during these stages may be to 
support cell survival by antagonizing apoptosis.  However, it is also possible that during 
cellular proliferation and differentiation, metabolic demands on the mitochondria are 
modulated.  Thus, MCL-1's critical function during such stages may be to facilitate 
mitochondrial fitness thereby opposing increased demands for oxidative phosphorylation.  
We anticipate that genetic studies separating MCL-1's functional role at the OMM and 
matrix will be necessary to delineate the contribution of these roles to normal cellular 
development and survival. 
 
 
MCL-1 in Embryonic Development 
 
Germline ablation of Mcl-l in mice results in an early preimplantation embryonic 
lethality at embryonic day 3.5 and, specifically, the embryos have a defective 
trophoectoderm (Rinkenberger et al., 2000).  Other anti-apoptotic BCL-2 family 
members do not display such a severe developmental phenotype, suggesting that MCL-1 
plays a unique role during early embryonic development.  While apoptosis is extremely 
important during development, none of the other apoptotic regulators are required at such 
an early embryonic developmental stage (Ranger et al., 2001).  Mitochondria have been 
shown to play an important role during the preimplantation stage embryo as aerobic 
metabolism is the primary source of ATP in the mouse blastocyst (Benos and Balaban, 
1983).  Furthermore, mitochondria in the trophoectoderm of the blastocyst have a high 
inner membrane potential, indicating that these mitochondria are actively respiring, 
which is important for early embryonic development (Van Blerkom et al., 2006). 
Precisely why Mcl-1 is required for implantation has remained elusive.  One possibility is 
that MCL-1 facilitates mitochondrial energy production that is required for differentiation 
of cytotrophoblasts into the intermediate trophoblast and the syncytiotrophoblast. Failure 
of the cytotrophoblasts to differentiate could result in a defective trophoectoderm that is 
unable to implant.  Another possibility is that MCL-1 is requisite for the mitochondria in 
the trophoectoderm to produce enough energy to allow invasion of the placenta. For these 
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reasons, it is plausible that MCL-1’s role during embryonic development is not only to 
antagonize cell death but is also to promote normal mitochondrial function, assisting in 
differentiation and placental invasion of the trophoblast cells that compose the blastoyst.  
To determine if the anti-apoptotic or the mitochondrial functions of MCL-1 are important 
for early embryonic development, a knock-in gene targeting strategy using MCL-1 OM or 
MCL-1Matrix could be used.  If neither MCL-1 OM nor MCL-1Matrix is sufficient for 
embryonic development then both functions of MCL-1 may be required.  In that case, a 
polycistronic viral vector can be utilized to co-express both MCL-1 OM and MCL-1Matrix. 
 
 
MCL-1 in Hematopoiesis 
 
The BCL-2 family members are important regulators of hematopoiesis. While 
transgenic expression of BCL-2 in hematopoietic stem cells (HSCs) can increase their 
numbers in vivo (Domen et al., 2000), mice that are deficient for Bcl-2 or Bcl-x deficient 
ES cells can both still produce hematopoietic cells; however, they exhibit effects later 
during specific lineage development (Motoyama et al., 1995; Veis et al., 1993).  Instead, 
MCL-1 is the key pro-survival molecule during hematopoiesis as inducible deletion of 
Mcl-1 results in rapid multi-lineage hematopoietic failure (Opferman et al., 2005). Along 
these lines, MCL-1 is unique because it is the essential survival factor for all early 
hematopoietic lineages.   
 
The hematopoietic system gives rise to a variety of mature cells including 
myeloid and lymphoid lineages.  HSCs maintain their populations through a balance of 
self-renewal and differentiation and it is unclear how much of a direct role apoptosis has 
in the regulation of this balance.  In contrast, the more committed lineages, such as 
lymphocytes are potently regulated by apoptosis particularly through regulation by 
cytokines and growth factors (Opferman, 2007; Opferman and Korsmeyer, 2003). 
Evidence has shown that HSCs have a low mitochondrial membrane potential and are 
predominantly glycolytic (Simsek et al., 2010). This metabolic phenotype is a 
consequence of the hypoxic niche in the bone marrow (Simsek et al., 2010).  
Furthermore, long-term hematopoietic stem cells (LT-HSCs), which retain the capacity to 
self-renew, are in a quiescent state with a reduced metabolic rate (Wilson et al., 2008).  In 
contrast, differentiation into the more committed progenitor cells is a high-energy 
demand process that requires mitochondrial function (Inoue et al., 2010).   
 
Accordingly, the profound requirement for Mcl-1 in hematopoietic stem cells may 
result from a synergy of both the anti-apoptotic and mitochondrial functions.  It is 
possible that the signals for differentiation and proliferation are coupled such that matrix-
localized and outer membrane-localized MCL-1 cooperate to provide increased energy 
upon differentiation into progenitor and antagonize apoptosis to sustain maintenance of 
the stem cell pool (Fig. 4.1).  Nevertheless, Mcl-1 may have separate roles in distinct 
hematopoietic lineages.   For example, matrix-localized MCL-1 may be important for 
early progenitors where proper mitochondrial function is required for differentiation 
whereas anti-apoptotic MCL-1 may be important for survival of the mature cells (Fig. 
4.1).   
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Figure 4.1. Possible MCL-1 Functions in Normal Homeostasis 
In normal stem cells, it is possible that the homeostatic control on self-renewal is 
regulated primarily by MCL-1’s OMM anti-apoptotic activity.  In contrast, the 
proliferation and differentiation of stem cells into progenitors and terminally 
differentiated lineages may require efficient energy production promoted by the truncated 
MCL-1 targeted to the matrix.  Lastly, proper homeostasis of terminally differentiated 
cells is likely controlled primarily by MCL-1’s OMM anti-apoptotic activity. 
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MCL-1 in the Brain 
 
The requirement of Mcl-1 in the developing nervous system further illustrates the 
significance of this pro-survival molecule.  In the absence of Mcl-1 widespread apoptosis 
occurs in the embryo resulting in embryonic lethality at embryonic day 16 (Arbour et al., 
2008).  The development of the cerebral cortex is heavily dependent on apoptosis in order 
to select for appropriate cortical neurons before differentiation (Blaschke et al., 1996) 
Therefore, MCL-1 may help maintain the balance between proliferation and cell death 
during embryonic development of the cerebral cortex.  However, in addition to apoptosis, 
neurons are extensively dependent on mitochondrial dynamics.  The imbalance between 
healthy and dysfunctional mitochondria can be a determinant for neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s (Chen et al., 2007).  Mitochondria are 
abundant in synaptic regions since synaptic transmission requires a high ATP demand 
(Chan, 2006).  It is possible that the different functional roles of MCL-1 at the OMM and 
the matrix may have different spatial and temporal requirements for maintaining neuronal 
survival and health.  For example, during development of the nervous system, while 
neurons are being established and eliminated, the anti-apoptotic role of MCL-1 on the 
OMM may be the principal function.   Anti-apoptotic MCL-1 may be necessary to 
maintain the balance between life and death in developing neurons that are controlled by 
homeostatic selection processes.  In comparison, MCL-1 may have an additional 
functional role in adult neurons.  Mitochondrial fusion is necessary for mitochondria to 
travel long distances from the neuronal cell body to the axonal termini where they 
generate ATP, particularly in the motor and sensory neurons that enervate the hands and 
feet.  In addition to antagonizing cell death, MCL-1 may also promote mitochondrial 
fusion in post-mitotic neurons. 
 
 
Role of MCL-1 in Cancer and Cancer Therapy 
 
MCL-1 is one of the most highly amplified genes in a variety of human cancers 
(Beroukhim et al., 2010); therefore, it is imperative to understand the contribution of 
MCL-1’s functions to oncogenesis.  Furthermore, its expression is often associated with 
chemotherapeutic resistance and relapse (Wei et al., 2006; Wuilleme-Toumi et al., 2005).  
In many malignancies, MCL-1 appears to be a critical survival molecule.  For instance, 
MCL-1 is critical for the development and maintenance of acute myeloid leukemia 
(Glaser et al., 2012; Xiang et al., 2010).  Moreover, MCL-1 overexpression dramatically 
accelerates Myc-induced lymphomagenesis (Campbell et al., 2010).  Similar to studies in 
normal cells, the majority of investigations into the role of Mcl-1 in mouse models of 
cancer have genetically ablated both the anti-apoptotic and the mitochondrial functions of 
MCL-1 making it difficult to separate the functional contributions of MCL-1’s anti-
apoptotic and mitochondrial functions.    
 
Oncogenesis can activate tumor suppressor pathways that frequently initiate cell 
death pathways.  Cancer cells often violate these key cellular checkpoints that would 
normally drive the cells to die by programmed cell death. As a result, they often 
overcome the apoptotic stress either by reducing the expression of pro-apoptotic factors 
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or, more frequently by up regulating anti-apoptotic molecules (Hanahan and Weinberg, 
2011). For example, the amplification of Myc is one of the most frequent oncogenic 
occurrences observed in human cancers and drives carcinogenesis (Beroukhim et al., 
2010).  Oncogenic levels of Myc induce apoptosis that must be overcome in part by over-
expression of anti-apoptotic molecules (Bissonnette et al., 1992; Eischen et al., 2001; 
Evan et al., 1992; Shi et al., 1992; Zindy et al., 1998).  Accordingly, the anti-apoptotic 
function of MCL-1 and other anti-apoptotic family members may be obligate in their 
promotion of survival as a result of oncogenic stress. 
 
Nevertheless, cancer cells are often rapidly dividing and require increases in 
biomass to support abnormal proliferation.  Although cancer cells often metabolize 
extremely high levels of glucose by glycolysis, glutamine is another essential metabolite 
that is excessively consumed through glutaminolysis (Eagle, 1955; Reitzer et al., 1979).  
Glutamine is a mitochondrial-oxidizable substrate that is essential for macromolecular 
synthesis of nucleic acids, proteins, and lipids required for assembling new cells 
(DeBerardinis et al., 2007).   In particular, oncogenic Myc has been linked to increased 
glutaminolysis through activation of a transcriptional program that renders cancer cells 
glutamine dependent (Wise et al., 2008; Yuneva et al., 2007). 
 
Since Mcl-1 is requisite for oncogenesis of Myc leukemia (Xiang et al., 2010) it is 
conceivable that both the anti-apoptotic and mitochondrial functions of MCL-1 play an 
important role in promoting the survival of Myc-induced cancer.  Myc transformation 
causes cells to become dependent on anti-apoptotic molecules in order to overcome 
apoptotic stress; therefore, the anti-apoptotic activity of MCL-1 may be indispensable.  
Nevertheless, it is possible that the non-apoptotic function of MCL-1 may help fulfill the 
requirements for rapid cell proliferation in Myc-cancer cells by facilitating the generation 
of byproducts from mitochondrial metabolism (DeBerardinis et al., 2007; Deberardinis et 
al., 2008). 
 
 
Cancer Stem Cells and Differentiation Therapy 
 
Normal stem cells undergo self-renewing cell division, which means they 
generate daughter cells that have the ability to self-replicate and produce more 
differentiated cell lineages (Rossi et al., 2008).  Cancer stem cells are defined as cancer 
cells that are capable of self-renewal and can give rise to a heterogeneous population of 
cancer cells (Vermeulen et al., 2008). For this reason, cancer stem cells can only be 
defined experimentally by their ability to generate the same clonal tumor when serially 
transplanted into immuno-compromised mice (Vermeulen et al., 2008).  If cancer stem 
cells are ultimately responsible for tumor maintainance then a theurapeutic strategy 
capable of depleting the cancer stem cell pool may control malignancy.  One potential 
way to deplete a cancer stem cell population is to induce the differentiation of the stem 
cells.  As previously mentioned, differentiation is a process that requires increased 
mitochondrial function and, for this reason, the role of MCL-1 inside the matrix may be 
to facilitate differentiation.  If matrix-localized MCL-1 promotes differentiation, then 
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utilizing the MCL-1Matrix mutant as a strategy to induce differentiation and deplete the 
cancer stem cell pool may be an alternative strategy to treat cancer. 
 
 
BCL-2 Family Inhibitors 
 
There has been an increasing interest in developing BCL-2 family inhibitors as a 
cancer therapeutic strategy, focusing on antagonizing anti-apoptotic activity to foster cell 
death (Oltersdorf et al., 2005).  One such inhibitor, obatoclax, is a BH3-mimetic that 
binds to BCL-2, BCL-XL, and MCL-1 to disrupt their interaction with the pro-apoptotic 
molecules (Nguyen et al., 2007).  Although obatoclax exhibits single-agent activity and 
can kill certain types of cancer cells in-vitro, it also has non-specific effects in which non-
apoptotic cell death occurs (Li et al., 2008; McCoy et al., 2010; Tse et al., 2008). 
Additionally, ligands and modified peptides that are also BH3-mimetics modeled 
specifically for MCL-1’s BH3-binding groove have been developed but to date appear to 
be only effective when combined with chemotherapeutic agents (Lee et al., 2008; Stewart 
et al., 2010b).  One possibility for the lack of single-agent activity is that these BH3-
mimetics only antagonize MCL-1’s anti-apoptotic activity leaving its mitochondrial 
function unaffected; thus, they may be insufficient to promote cell death unless combined 
with another death-inducing agent.  Paradoxically, genetic deletion of Mcl-1 induces cell 
death in cancer cells regardless of complementary expression of other endogenous anti-
apoptotic family members (Glaser et al., 2012; Xiang et al., 2010).  Only when other anti-
apoptotic BCL-2 family members are ectopically expressed can loss of MCL-1 be 
tolerated in these cancer cells (Glaser et al., 2012; Xiang et al., 2010).  Thus, it is possible 
that the non-apoptotic, mitochondrial function of MCL-1 is important to promoting 
cancer cell survival and proliferation, but that overexpression of pro-survival molecules 
can overcome this stress.  In light of the potential for MCL-1 to promote both cancer cell 
apoptotic resistance and to support the high rate of proliferation often observed in cancer 
cells, it is possible that inhibition of both the anti-apoptotic and mitochondrial functions 
of MCL-1 may synergize by restricting cancer cell expansion and activating cell death, 
thereby leading to more effective therapies. 
 
 
Post-translational Regulation of MCL-1 
 
Although MCL-1 has been shown to be ubiquitinated by several E3 ligases 
including, MULE, ßTRCP and FBW7, it is difficult to observe both the 40 kD and 36 kD 
isoforms of MCL-1 in these studies (Ding et al., 2007; Inuzuka et al., 2011; Zhong et al., 
2005).  However, the different MCL-1 isoforms were shown to possess different protein 
half-lives (De Biasio et al., 2007; Stewart et al., 2010a).  For example, full length (40 kD) 
MCL-1 has an extremely short half-life, approximately 2 hours, while the N-terminally 
cleaved isoform (36 kD) is greater than 6 hours (Stewart et al., 2010a).  This may be due 
to the differential localization of these MCL-1 isoforms, since the turnover of outer 
membrane and inner membrane proteins of the mitochondrion are quite different 
(Brunner and Neupert, 1968).  The average half-life of outer mitochondrial membrane 
proteins was found to be ~4 days, which differs considerably from the half-life of inner 
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membrane proteins, ~12 days (Brunner and Neupert, 1968).  In addition to observing that 
the MCL-1 isoforms have differential protein turnover rates, Stewart et al. also generated 
a lysine-less MCL-1 mutant where 14 lysine residues were mutated to arginine (MCL-
1KR)(Stewart et al., 2010a).  This mutant was unable to be ubiquitinated but, surprisingly 
did not change the turnover rate of the 40 kD MCL-1 isoform, however, dramatically 
changed the half-life of the 36 kD isoform from greater than 6 hours to ~2 hours (Stewart 
et al., 2010a).  These observations are unexpected because MCL-1KR was predicted to 
increase MCL-1 half-life since it could not be marked for degradation by the proteasome.  
A simple explanation for the rapid turnover of the 36 kD isoform of MCL-1KR is that this 
mutant protein is not properly folding inside the mitochondria due to the 14 point 
mutations which may cause aberrations in the protein secondary structure. Consequently, 
the 36 kD isoform of MCL-1KR may be misfolded and degraded inside the mitochondrial 
matrix by the AAA+ family of ATPases, such as Lon and ClpXP (Tatsuta and Langer, 
2008).  This hypothesis could simply be tested by RNA interference against Lon or 
ClpXP proteases then monitoring MCL-1KR half-life.  An alternative explanation is that 
MCL-1 undergoes protein acetylation, which may facilitate the binding of another 
adaptor protein that is important for MCL-1 protein stability inside the mitochondria. 
MCL-1KR cannot be acetylated, due to the lack of lysine residues, and therefore 
dissociates with its binding partner, destabilizing the 36 kD isoform.  In order to test if 
MCL-1 is acetylated, tandem mass spectroscopy can be used to identify potential MCL-1 
acetylation sites.  Validation of acetylation could be carried out by labeling cells with 
[H3]acetate, immunoprecipitating MCL-1 then analyzing via fluorography.  
 
Despite observations that MCL-1 protein is rapidly degraded by the proteasome, 
inhibition of the proteasome did not result in increased expression of the 40 kD isoform, 
rather, it led to accumulation of the 38 kD isoform (De Biasio et al., 2007; Stewart et al., 
2010a).  Indeed, findings from De Biaso et al. revealed that full length MCL-1 was 
continually processed to the 36 kD isoform (De Biasio et al., 2007).  Furthermore, the 
processing of MCL-1 to the 36 kD form was shown to depend on a functional 
mitochondrial membrane potential, suggesting that the cleavage occurs inside the 
mitochondria (Warr et al., 2011).  Along these lines, RNAi-mediated silencing of the 
mitochondrial processing peptidase (MPP) ablated the formation of the 36 kD isoform of 
MCL-1, indicating that MCL-1 processing takes place in the matrix (Huang and Yang-
Yen, 2010).  In addition to proteasome-dependent degradation, proteolytic cleavage of 
full-length MCL-1 may represent another mechanism for regulating its protein turnover.  
It is possible that both inhibiting the proteasome and dissipating the mitochondrial 
membrane potential may dramatically increase the half-life of full length MCL-1.  To that 
end, the MCL-1OM mutant could be predicted to have a longer half-life because it is 
unable to be proteolytically cleaved, and therefore accumulates on the OMM.  
Alternatively, MCL-1 OM could have a shorter half-life due to easier access by the 
proteasome. 
 
Differential regulation of MCL-1 isoforms resulting from a variety of cellular 
stresses has also been documented.  For example, DNA-damaging agents such as 
etoposide and UV irradiation both increased the turnover rate of the 40 kD isoform with 
no effect on the 36 kD form of MCL-1 (De Biasio et al., 2007; Stewart et al., 2010a).  
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However, this may just be a reflection of the differential half lives of the two isoforms.   
In contrast, nutrient-induced stress, such as cytokine or glucose withdrawal, appears to 
reduce the levels of both isoforms of MCL-1 (Coloff et al., 2011; Maurer et al., 2006).  
However, the nutrient deprivation appears to be regulating MCL-1 translation via mTOR 
and could explain why there is less of both isoforms (Coloff et al., 2011; Pradelli et al., 
2010). 
 
 
Regulation of Mitochondrial Function by MCL-1 
 
My data suggests a new role of MCL-1 in regulating mitochondrial metabolism 
and dynamics; a function separate from its ability to antagonize cell death that requires its 
import into the mitochondrial matrix.  During import, the MCL-1 protein undergoes 
amino-terminal proteolytic cleavage resulting in the production of multiple proteins from 
the same polypeptide.  The generation of the matrix-localized MCL-1 requires two 
proteolysis events and importation into the mitochondria by the translocases of the outer 
and inner membrane (TOM and TIM complexes).  It has also been shown that full-length 
MCL-1 continually undergoes processing to the matrix-localized isoform that depends on 
a functional mitochondrial membrane potential and may be processed by the MPP inside 
the mitochondrial matrix (De Biasio et al., 2007; Huang and Yang-Yen, 2010; Warr et 
al., 2011).  Further studies will be required to identify whether cleavage at both sites 
occurs within the mitochondria and/or whether other cellular proteases are involved. 
 
Functionally, the OMM-localized MCL-1 possesses anti-apoptotic activity, 
inhibiting cell death and binding pro-apoptotic molecules (Fig. 4.2). In contrast, the 
matrix-localized MCL-1 does not possess anti-apoptotic function, but instead facilitates 
normal mitochondrial physiology and energy metabolism.  The matrix-localized MCL-1 
promotes normal mitochondrial ultrastructure by maintaining cristae morphology as well 
as the dynamics of mitochondrial fusion.  Additionally, the MCL-1 matrix isoform 
supports oxidative phosphorylation, ATP production and maintenance of mitochondrial 
membrane potential.  Thus, MCL-1 functions both to directly oppose apoptosis and to 
promote mitochondrial physiology. 
 
 
MCL-1 Modulates Inner Membrane Structure, Dynamics, and Function 
 
While my data suggests that MCL-1 is required inside the mitochondrial matrix 
for normal mitochondrial cristae structure, fusion, and bioenergetics, including oxidative 
phosphorylation (OXPHOS), precisely how MCL-1 can promote this function is still 
uncertain.  Mitochondrial morphology, dynamics, and function are closely linked.  
Particularly, the structure of the inner membrane is highly organized and dynamic.  The 
mitochondrial cristae are pleomorphic and adapt different structures according to the 
metabolic status of the cell.  For example, when ADP is low and ATP is abundant the 
cristae are short and flat with fewer cristae junctions and an expanded matrix, called 
“orthodox” (Hackenbrock, 1968).  Whereas, under conditions of high ADP and low ATP, 
the cristae have multiple tubular connections and a compact matrix, called “condensed”  
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Figure 4.2. Classical Anti-apoptotic MCL-1 
On the outer mitochondrial membrane (OMM), MCL-1 functions like other antiapoptotic 
BCL-2 family members where it antagonizes the activation of BAX and BAK and 
prevents cell death.  MCL-1 can directly bind BH3-only family members, such as BIM,  
sequestering them away from the pro-apoptotic effectors BAX or BAK.  Alternatively,  
MCL-1 may directly bind BAX and BAK and maintain them in an inactive conformation. 
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(Hackenbrock, 1968).  Since cells lacking MCL-1 inside the mitochondrial matrix have 
profound deficits in bioenergetics, it is possible that MCL-1 may directly modulate the 
function of one or more of the ETC components.   In the absence of matrix-localized 
MCL-1, the capacity for OXPHOS is diminished and ATP production plummets, thereby 
indirectly affecting the cristae morphology and dynamics.   
 
However, it is also possible that the dynamic transition between “orthodox” and 
“condensed” requires an active fission and fusion process and MCL-1 could directly 
modify this process.  For example, MCL-1 could influence the function of OPA1, a well-
characterized regulator of inner membrane fusion.  In the absence of MCL-1 inside the 
mitochondrial matrix, OPA1 activity may be perturbed resulting in fusion defects.  
Furthermore, defects in mitochondrial fusion cause dysfunctional mitochondria.  Cells 
that are fusion incompetent generate less energy by OXPHOS and have increased ROS 
production in addition to fragmented mitochondria (Chen et al., 2005a; Chen et al., 
2007).  This is because fusion maintains a healthy mitochondrial population through the 
exchange of contents between mitochondria including mtDNA. The mtDNA genome is 
organized into nucleoids and encodes for essential components of the respiratory chain.  
Fusion enables the exchange of mtDNA nucleoids between mitochondria, however, in 
cells incapable of fusion there is a loss of nucleoids (Chen et al., 2007; Legros et al., 
2004).  Consequently, a possible explanation for the decreased mtDNA content observed 
in Mcl-1-deleted cells may be an effect of incompetent mitochondrial fusion; 
subsequently, resulting in bioenergetic abnormalities such as inefficient respiration and 
decreased membrane potential.  Moreover, mitochondrial membrane potential influences 
fusion efficiency (Song et al., 2007) and, therefore could cause a feed-forward inhibition 
of fusion rate.  
 
Alternatively, MCL-1 may regulate inner membrane structure by directly 
facilitating the dimerization and oligomerizaton of F1F0-ATP synthase.  ATP synthase 
dimers and oligomers constrain and curve the IMM and this is required for maintaining 
the proper organization of the IMM (Dudkina et al., 2005; Giraud et al., 2002; Thomas et 
al., 2008). The assembly of ATP synthase into dimers and oligomers is aberrant in 
mitochondria lacking MCL-1 (Fig. 4.3).  It is possible that MCL-1 is an accessory protein 
that bridges either the F1 or F0 domains, stabilizing the complex (Fig. 4.3).  On the other 
hand, MCL-1 could indirectly support dimerization through another accessory protein 
such as inhibitory factor 1 (IF1).  IF1 is a protein that binds to ATP synthase and prevents 
the hydrolysis of ATP (Pullman and Monroy, 1963).  IF1 regulates mitochondrial 
ultrastructure by promoting dimerization of ATP synthase (Campanella et al., 2008). 
 
  Mcl-1-deleted mitochondria exhibit a loss of oligomeric ATP synthase and a 
corresponding increase in monomeric form, indicating that those oligomers are less stable 
in the absence of MCL-1.  It is plausible that the loss of ATP synthase oligomers in Mcl-
1-deleted mitochondria may be responsible for the ultrastructural defects including 
disorganized cristae.  Similar defects were seen in the assembly of electron transport 
chain (ETC) complexes into “supercomplexes” in MCL-1 deficient mouse liver 
mitochondria (Fig. 4.3).  It has been demonstrated that the assembly of the ETC 
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Figure 4.3. MCL-1’s Potential Functions Inside Mitochondria 
During mitochondrial importation, the full-length MCL-1 is proteolytically truncated on 
its amino-terminus.  The truncated, matrix localized MCL-1 resides within the inner 
mitochondrial membrane where it functions to maintain mitochondrial cristae 
ultrastructure and promotes the assembly of the electron transport chain complexes into 
higher-order assemblies known as supercomplexes (SC).  The assembly into 
supercomplexes has been shown to facilitate electron transport efficiency and reduce the 
production of deleterious reactive oxygen species.  Additionally, matrix-localized MCL-1 
facilitates the assembly of the higher-order assembly of the ATP synthase complexes into 
dimers and oligomers.  Proper assembly of oligomeric ATP synthase has been implicated 
in being an important determinate of inner membrane cristae structure.  Whether MCL-1 
acts directly or indirectly to facilitate these macromolecular assemblies of the electron 
transport supercomplexes or ATP synthase oligomers is still unclear. 
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complexes into supercomplexes promotes efficient energy production and decreases the 
production of harmful reactive oxygen species (Acin-Perez et al., 2008).  Since 
abnormalities in mitochondrial cristae ultrastructure can promote the breakdown of the 
reticular mitochondrial network, this could explain the observed mitochondrial fusion 
defect and subsequent bioenergetic abnormalities in Mcl-1-deficient cells (Velours et al., 
2009).   
 
Another possible cause of the ultrastructural defects is an aberrant lipid inner 
mitochondrial membrane.  MCL-1 may directly or indirectly regulate the lipid content of 
the inner mitochondrial membrane.  For example, MCL-1 could facilitate the structure 
and/or function of cardiolipin.  Cardiolipin is an abundant lipid in the inner mitochondrial 
membrane that affects mitochondrial ultrastructure and function (Houtkooper and Vaz, 
2008).  Furthermore, cardiolipin regulates supercomplex assembly of the repiratory 
complexes and ATP synthase oligomerization (Wittig and Schagger, 2009).  It is possible 
that MCL-1 could indirectly affect cardiolipin structure.  In the absence of MCL-1, 
cardiolipin structure may be disrupted and this could alter the fusion of the lipids in the 
inner mitochondrial membrane.  Indeed, the lipid structure is very important for 
membrane fusion (Cullis et al., 1986).  Alternatively, MCL-1 could directly interact with 
cardiolipin to facilitate its function, such that in the absence of this interaction a 
functional change occurs, possibly even disrupting other cardiolipin complexes.  
 
 
Concluding Remarks 
 
My findings regarding MCL-1-regulated mitochondrial physiology and its 
separable functions as an anti-apoptotic molecule at the OMM and regulator of 
mitochondrial bioenergetics inside the matrix, may have a major impact in our 
understanding of MCL-1 biology in normal cells, and represent a new clinical target.  
Recently, another anti-apoptotic BCL-2 family member, BCL-XL, was found inside the 
mitochondrial matrix where it also played a role in mitochondrial metabolism (Alavian et 
al., 2011).  While BCL-XL was found to regulate mitochondrial metabolism, there was no 
indication that it played a role in mitochondrial morphology (Alavian et al., 2011).  For 
this reason, BCL-XL may be able to functionally compensate for the metabolic role of 
MCL-1 inside the mitochondrial matrix.   Additionally, if BCL-XL was also able to 
compensate for the morphology abnormalities observed in Mcl-1-deficient cells, this 
would suggest that the regulation of mitochondrial metabolism is MCL-1’s primary role 
inside the mitochondria.  Undoubtedly, defining the mechanism by which MCL-1 
regulates mitochondrial physiology as well as identifying MCL-1-interacting partners 
inside the mitochondrial matrix will be important to understanding its function.  Future 
studies delineating the relative contributions of MCL-1’s anti-apoptotic and metabolic 
functions in both normal and diseased cells may help to develop more effective MCL-1 
inhibitors with reduced toxicity to normal cells.    
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